

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/23760634>

Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping

ARTICLE in JOURNAL OF MEDICINAL CHEMISTRY · FEBRUARY 2009

Impact Factor: 5.45 · DOI: 10.1021/jm801220a · Source: PubMed

CITATIONS

50

READS

39

6 AUTHORS, INCLUDING:



Huiying Li

University of California, Irvine

106 PUBLICATIONS 3,638 CITATIONS

SEE PROFILE



Pavel Martasek

Charles University in Prague

298 PUBLICATIONS 8,993 CITATIONS

SEE PROFILE



Linda J Roman

University of Texas Health Science Center at ...

135 PUBLICATIONS 4,329 CITATIONS

SEE PROFILE



Thomas L Poulos

University of California, Irvine

163 PUBLICATIONS 4,489 CITATIONS

SEE PROFILE

Published in final edited form as:

J Med Chem. 2009 February 12; 52(3): 779–797. doi:10.1021/jm801220a.

Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping

Haitao Ji[†], Huiying Li[†], Pavel Martíásek^{§,¶}, Linda J. Roman[§], Thomas L. Poulos[‡], and Richard B. Silverman^{*,†}

[†]Department of Chemistry, Department of Biochemistry, Molecular Biology, and Cell Biology, and Center for Drug Discovery and Chemical Biology, Northwestern University, Evanston, Illinois 60208-3113

[‡]Departments of Molecular Biology and Biochemistry, Pharmaceutical Chemistry, and Chemistry, University of California, Irvine, California 92697-3900

[§]Department of Biochemistry, The University of Texas Health Science Center, San Antonio, Texas 78384-7760

[¶]Department of Pediatrics, First Faculty of Medicine, Charles University, Prague, Czech Republic

Abstract

Selective inhibition of neuronal nitric oxide synthase (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity, but more drug-like properties can be achieved by fragment hopping. Based on the structure of lead molecule **6**, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better drug-like properties were obtained within the design of 20 derivatives (compounds **7-26**). Our structure-based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known drug-like small-molecule modulators are still limited.

Introduction

Fragment-based drug discovery has been recognized as a tangible alternative to more traditional methods of hit identification, such as high throughput screening (HTS).¹ This approach was designed to screen a small collection of basic chemical building blocks (fragments) with molecular weights in the range of 120-250 Da and then to enlarge or to link them into high-affinity compounds.² Recently we established a new fragment-based de novo design strategy,³ termed *fragment hopping*.⁴ The core of this approach is the determination of the minimal pharmacophoric elements, which are smaller than fragments, can be a cluster of atoms, virtual graphs and/or vectors. Based on each minimal pharmacophoric element, various fragments with different chemotypes can be generated with the aid of a basic fragment library and a bioisostere library. The fragments corresponding to each pharmacophoric element were then linked/hybridized into larger molecules. The advantages of our new approach are: (1) It can explore a much wider chemical space, and (2) it can effectively characterize and utilize the delicate differences in the active site that are responsible for isozyme selectivity. Consequently, it is able to generate more potent and selective inhibitors for isozymes.

*Corresponding author: Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208-3113, Phone: (847) 491-5653, Fax: (847) 491-7713, E-mail: Agman@chem.northwestern.edu.

Nitric oxide (NO),⁵ a highly reactive free radical, is an important and ubiquitous signaling molecule that plays a significant role in the regulation of a diverse set of mammalian physiological processes.⁶ Generally, NO acts as a potent activator of soluble guanylate cyclase (sGC) *via* its binding to the heme of the enzyme, which catalyzes the conversion of guanosine 5'-triphosphate (GTP) to an intramolecular second messenger, guanosine 3',5'-cyclic monophosphate (cGMP).⁷ This NO/cGMP signaling pathway is essential in many physiological processes including vasodilation, neurotransmission, and platelet aggregation.⁸ It is also well established that NO has some cGMP-independent actions.⁹

Nitric oxide is synthesized by a family of enzymes called nitric oxide synthase (NOS, EC 1.14.13.39), which catalyzes an NADPH- and O₂-dependent five-electron oxidation of L-arginine to L-citrulline and nitric oxide (NO) via the intermediate N^G-hydroxy-L-arginine.¹⁰ Three distinct isozymes of NOS have been identified in mammals,¹¹ products of different genes, with different subcellular localization, regulation, catalytic properties, and inhibitor sensitivity. Three mammalian NOSs show 50-60% sequence homology, and each is associated with a different physiological function: neuronal nitric oxide synthase (nNOS), which generates NO in the CNS, is involved in neurotransmission and long-term potentiation; endothelial nitric oxide synthase (eNOS) derived NO is involved in the regulation of smooth muscle relaxation and vascular tone; and a third, inducible isoform in macrophages (iNOS), is important in the immune system defense against pathogens and tumor cells.¹²

NOS is active as a homodimer with each subunit containing a C-terminal reductase domain (with binding sites for NADPH, FAD, and FMN) and a N-terminal oxygenase domain containing the heme prosthetic group. The substrate L-arginine and a redox cofactor, (6*R*)-5,6,7,8-tetrahydro-L-biopterin (H₄B), both bind near the heme center in the oxygenase domain.¹³ nNOS and eNOS are constitutively expressed and intermittently produce small amounts of NO. In contrast, iNOS is inducible by cytokines and produces a large amount of NO for both a cytoprotective and cytotoxic effect. The constitutive enzymes bind calmodulin (CaM) reversibly in a Ca²⁺-dependent manner, and their activity is regulated by local Ca²⁺ concentration, while iNOS does not depend on the intracellular calcium level because iNOS carries CaM as a permanently bound subunit. Electrons are transferred from NADPH *via* FAD and FMN to the heme of the other subunit. This flow of electrons during catalysis occurs from the reductase domain of one monomer to the oxygenase domain of the other monomer, so an intact homodimeric form of the enzyme is essential for full enzyme activity.

Overproduction of NO from nNOS has been associated with harmful effects in the central nervous system, including acute (stroke)¹⁴ and chronic (Alzheimer's disease, Parkinson's disease, schizophrenia, and AIDS dementia) outcomes.¹⁵ Radical nitric oxide (NO·) can react rapidly with superoxide (O₂⁻) in aqueous media to generate the highly reactive peroxynitrite anion (ONOO⁻). Either nitric oxide or peroxynitrite causes oxidative damage and/or protein nitration and, therefore, leads to neurodegeneration.¹⁶ Overproduction of iNOS has been implicated in various pathological processes including septic shock, tissue damage following inflammation, and rheumatoid arthritis.¹⁷ In contrast, NO produced by eNOS in endothelial cells has mainly physiological roles, such as maintaining normal blood pressure and flow.¹⁸ Accordingly, inhibition of nNOS or iNOS, but not of eNOS, could provide an effective therapeutic approach.¹⁹ On the other hand, selective inhibitors could also be useful tools for investigating other biological functions of NO.²⁰ The research goal of our laboratories has been to develop selective nNOS inhibitors.²¹

The crystal structures of the dimeric oxygenase domain for all three NOS isozymes have been solved,²² which provide the possibility for structure-based inhibitor design. However, this has proven to be a challenging problem because the active sites of NOS isozymes are highly conserved. Sixteen out of eighteen residues within 6 Å of the substrate binding site are identical,

and the side chain of one of these two dissimilar amino acids points out of the substrate-binding site.²³ Previously, we synthesized and evaluated nitroarginine-containing dipeptide or peptidomimetic inhibitors and identified a family of compounds that had high potency and selectivity for inhibition of nNOS over eNOS and iNOS. The most potent nNOS inhibitors among these compounds were **1**,²⁴ **2**,²⁵ **3**,²⁶ **4**,²⁷ and **5**.²⁸ (Table 1). The selectivity of the dipeptide/peptidomimetic inhibitors for nNOS over eNOS and/or iNOS was investigated by crystallographic analysis²⁹ and by computer modeling (GRID/CPCA).³⁰

Starting with nitroarginine-containing dipeptide inhibitors, fragment hopping derived the minimal pharmacophoric elements and utilized the minute structural differences of the active sites of the three NOS isozymes, leading to the design of a non-peptide small organic molecule **6**, which exhibits nanomolar nNOS inhibitory potency and 1000-fold nNOS selectivity over eNOS (Table 1).⁴ The crystal structure of nNOS in complex with **6** showed a bioactive conformation of **6** as predicted and mimic the mode of action of the dipeptide nNOS inhibitors.⁴ As an initial attempt of the new methodology, test molecule **6** in Table 1 was successful, but rather polar and not optimized sufficiently to possess *in vivo* potency and efficacy. In this study, we continued to use fragment hopping to evolve more potent and selective nNOS inhibitors from **6** with increased lipophilicity. The aim of this research was to see whether or not fragment hopping was able to generate more potent and nNOS-selective inhibitors with improved physicochemical and pharmacokinetic profiles. The relationships between structure and activity and/or isozyme selectivity were addressed to interrogate the robustness and effectiveness of the methodology.

Results and Discussion

Inhibitor Design

In fragment hopping, two software programs GRID³¹ and multiple copy simultaneous search (MCSS)³² are the assistant tools used to explore potential pharmacophoric elements for the binding with the active site. In this study we continued to use these tools to investigate the active site of nNOS based on the scaffold of **6**. As discussed earlier^{4,30}, the active site of NOS can be divided into four pockets. The S pocket is above the heme ring, which is the catalytic site for the substrate, L-arginine. The M pocket is in between the substrate catalytic site and the substrate access channel. The C1 and C2 pockets are away from the substrate-binding cavity, and they constitute the substrate access channel. The schematic drawing shown in Figure 1 shows the NOS pockets targeted in this study. The residue numbering for rat nNOS, bovine eNOS, and murine iNOS are used in the following discussion because these are the sources of the NOS for the assay and NOS X-ray crystal structure data.

One fundamental requirement for the development of potent inhibitors of nNOS is that they must cross the blood brain barrier (BBB), a natural bodyguard of the brain. As **6** is a very polar molecule, one of major requirements for the structural optimization of **6** is to increase its lipophilicity. In the GRID analysis, hydrophobic interactions are calculated with the DRY probe. Two hydrophobic areas were identified by the DRY probe (Figure 2A and Table 2). One is a hydrophobic cavity surrounded by M336, L337, Y706, and W306 (from the second monomer) in the C1 pocket. The other one is a small cavity lined with the side chains of P565, A566, V567, and F584 in the S pocket. The C3, C1=, and NM3 probes describe steric interactions. Two significant molecular interaction fields (MIFs) in the active site of nNOS for steric probes have been described.³⁰ One is in the S pocket, and the other is located in the M pocket. However, compared to the position of the 2-aminopyridine group of **6** in the S pocket (Figure 2B), there is more space around position 4 of the 2-aminopyridine ring where the maximal molecular interaction energies are placed for the steric probes (-5.00 kcal/mol for the C3 probe, -5.30 kcal/mol for the C1= probe, and -12.50 kcal/mol for the NM3 probe). Furthermore, the cavity lined by M336, L337, Y706, and W306 in the C1 pocket is also

favorable for van der Waals contact (the maximal interaction energies are -3.50 kcal/mol, -3.30 kcal/mol and -8.20 kcal/mol for the C3, C1= and NM3 probes, respectively), as shown in Figure 2B and Table 2. The N1+ and N2+ probes were utilized to explore the possibility of substitution on the amino groups of **6**. It suggests that it is possible that the terminal amino group of the ethylenediamine side chain of **6** be modified into an sp³-hybridized NH cation (the maximal interaction energy is -10.00 kcal/mol in Table 2) or an sp³-hybridized NH₂ cation (the maximal interaction energy is -10.50 kcal/mol in Table 2). Halogen atoms are often considered, in structural optimization, to enhance potency/selectivity and *in vivo* efficacy. Two organic halogen probes Cl and F were used to explore the potential MIFs in the active site of nNOS, as indicated in Table 2.

Five apolar and hydrophobic functional groups (benzene, cyclohexane, isobutane, n-butane, and propane) have been mapped into the active site of nNOS by MCSS calculations. As discussed previously,⁴ the minima with the most favorable interaction energies for benzene, cyclohexane, and isobutane are located in the S pocket. This study shows that the minima with the most favorable interaction energies for n-butane (minima no. 1-no. 11: -10.85 kcal/mol ~ -8.58 kcal/mol) and propane (minima no. 1-no. 5: -9.99 kcal/mol ~ -8.71 kcal/mol) are also located in the S pocket lined by P565, A566, V567, F584, S585, G586, and the heme (Figure 3 and Table 3). Comparing the relative positions of the 2-aminopyridine ring of **6**, there is more space around position 4 of the 2-aminopyridine ring in the S pocket, as indicated by the heavy atom-only models (cyclohexane, isobutane, propane, and n-butane), which are appropriate to explore steric effects (Figure 3). Further analysis shows that there are minima displaying favorable interaction energies for the above five functional groups in the C1 pocket lined by M336, L337, Y706, and W306, as shown in Figure 3. Four of 27 minima of the benzene group are located in this pocket, and the lowest interaction energy is -13.47 kcal/mol (minimum no. 7). Others in this C1 pocket are 12 of 98 minima of the cyclohexane group (minimum no. 6: -7.08 kcal/mol), 4 of 22 minima of the isobutane group (minimum no. 13: -6.12 kcal/mol), 32 of 224 minima of the n-butane group (minimum no. 52: -5.70 kcal/mol), and 9 of 84 minima of the propane group (minimum no. 14: -5.71 kcal/mol). The trimethylamine cation and dimethylamine cation were also used to explore the possibility of substitution on the amino groups of **6** in the MCSS calculations. It is suggested in Table 3 that the terminal amino group of **6** can be modified to an sp³-hybridized NH cation (minima no. 2: -82.79 kcal/mol and no. 7: -73.98 kcal/mol for trimethylamine cation) or an sp³-hybridized NH₂ cation (minima no. 1: -131.52 kcal/mol and no. 11: -102.92 kcal/mol for dimethylamine cation).

The above GRID and MCSS calculations show that there is a small steric and hydrophobic cavity around position 4 of the 2-aminopyridine ring of **6**, which is lined with the side chains of P565, A566, V567, and F584 in the S pocket, and a hydrophobic cavity, lined with M336, L337, Y706, and W306 (from the second monomer) in the C1 pocket. These two hydrophobic/steric regions were used to generate the minimal pharmacophoric elements for better ligand potency, as well as better physicochemical and pharmacokinetic profiles. The structural modification targeting the S pocket is the introduction of a methyl group at position 4 of the 2-aminopyridine ring of **6**. The structural modification for the C1 pocket is the introduction of a phenyl group or a substituted phenyl group at the ethylenediamine side chain of **6**. Keeping the above minimal pharmacophoric elements in mind, several compounds were generated with the aid of the LUDI program³³ using the focused fragment libraries generated in the previous study.⁴ To better understand the structure-activity relationship of this series of inhibitors, the design process was divided into three stages (Figure 4). Stage A is the continuing study of the structure-activity relationships based on the structure of **6**; nine compounds were designed (Figure 4A). Stage B is the study of structure-activity relationships based on the structure of **15**; thirteen compounds were designed (Figure 4B). Stage C is the structural modification of **16** and **26** to increase molecular lipophilicity and decrease molecular polar surface area (PSA); four compounds were designed (Figure 4C).

Chemistry

Scheme 1 shows the synthetic route for **7-14**. The synthesis of **36** has been described in a previous paper.⁴ Direct reductive amination reactions were used to generate **37**. When 3 Å molecular sieves were used as a water trap, anhydrous MeOH was used as the solvent, one equivalent of acetic acid was used as the proton source, and sodium cyanoborohydride (NaBH_3CN) was used as the reducing agent, the yield of product was about 45-65%. The ratio of the *cis* to *trans* isomers was 45:55 for **7-9**, **11**, and **12**, but 18:82 for **10**, **13**, and **14**. When anhydrous MeOH was used as the solvent, one equivalent of acetic acid was used as the proton source, and catalytic hydrogenation (platinum IV oxide as catalyst) was used, the yield of product was still the same. However, the ratio of the *cis* and *trans* isomers was changed to 55:45 for **7-9**. When 3 Å molecular sieves were used as the water trap, 1,2-dichloroethane was used as the solvent, and sodium triacetoxyborohydride [$\text{NaBH}(\text{OAc})_3$] was the reducing agent, the yield of product was increased to 80-95%. The ratio of the *cis* and *trans* isomers was changed to 75:25 for **7-9**, **11**, and **12**, and 45:55 for **10**, **13**, and **14**. The *cis* and *trans* isomers can be completely separated by silica gel column chromatography. As discussed earlier,⁴ the ^1H NMR and ^{13}C NMR spectra of the *cis* and *trans* isomers are quite different for each isomer. One prominent difference is that the ^{13}C chemical shift of the methylene carbon atom attached to the pyridine ring is 29 ppm for the *cis* products, but 34 ppm for the *trans* isomers. The side chains of **41-43** were synthesized by Scheme 2B. The amino group of **38-40** was selectively protected with $(\text{Boc})_2\text{O}$ in 1M NaOH aqueous solution. Then the hydroxyl group was converted into an azido group by a Mitsunobu reaction. After hydrolysis of the azido compounds with triphenylphosphine in a THF/ H_2O mixture or by catalytic hydrogenation using 10% Pd/C, the pure compounds (**41-43**) can be obtained by silica gel column chromatography using a mixture of CH_2Cl_2 and MeOH as eluent.

The synthesis of **15-26** and **29** is shown in Scheme 2. The synthesis of **46** was described in a previous paper.²³ The amine compounds (**47**) were prepared by reductive amination using $\text{NaBH}(\text{OAc})_3$ as the reducing agent as mentioned above. The *cis* and *trans* isomers can be completely separated by silica gel column chromatography. The ratio of the *cis* and *trans* isomers was still 75:25. As discussed above, the *cis* and *trans* isomers were characterized and assigned by ^1H NMR and ^{13}C NMR spectra. Deprotection of the Boc groups of **47** afforded final products **15-26** and **29**. The synthesis of the amine side chains **53** are shown in Scheme 3B. The substituted phenylacetaldehydes were condensed with ethanolamine and then reduced with sodium borohydride (NaBH_4) to generate **48** in high yields ($\geq 94\%$), whereas direct reductive amination affords much lower yields (about 67%) if NaBH_3CN is used as the reducing agent, 3 Å molecular sieves as a water trap, one equivalent of acetic acid as the proton source, and anhydrous MeOH as the solvent. In the synthesis of **50**, direct reductive amination affords quantitative yields of the desired product. Benzyl protection of ethanolamine is necessary; otherwise, the dibenzylethyl substituted product will be obtained after reductive amination.

The syntheses of **30** and **31** were achieved by two different synthetic routes shown in Scheme 3A. By one way, **47b** or **47m** was subjected to reductive amination to generate methylated derivative **54** using formaldehyde as the carbon source, acetic acid as the proton source, and NaBH_3CN as the reducing reagent. The second approach was a direct reductive amination using $\text{NaBH}(\text{OAc})_3$ as the reducing reagent. **46** was allowed to react with **57** or **60** to generate *cis* isomer **55** exclusively. The synthesis of **32** was only carried out by the latter synthetic route. The synthesis of amine side chain **57** is shown in Scheme 3B. Alcohol **53** was oxidized to **56** with Dess-Martin periodinane. Then the aldehyde was converted to the secondary amine by an indirect reductive amination in almost a quantitative yield. In Scheme 3C, *N*¹,*N*²-dimethylethane-1,2-diamine was first monoprotected with Boc anhydride. Then it was treated with

aldehyde **49** to generate **59**; the Boc group of **59** was deprotected with TFA, and then the compound was basified to afford **60**.

In the early stage of this study, we discovered that *trans* alcohol **35** or **45a** were not able to be converted into the *cis* amine (**37** or **47**) by any S_N2 reaction, for example a Mitsunobu reaction or attempts to activate the hydroxyl group of **35** or **45a** as a tosylate, methylate, or triflate followed by displacement with a nitrogen-containing nucleophile. The only product generated from these attempted reactions is a new *cis* five-membered ring (a quarternary ammonium) that occurs by intramolecular attack of the nitrogen atom of the 2-aminopyridine on the carbon atom attached to the hydroxyl group. Consequently, alcohol **35** or **45a** were oxidized to ketones, and then reductive amination was carried out to generate **37**, **47**, and **55** as shown in Schemes 1-3. The disadvantage of these synthetic routes is that both the *cis* and *trans* isomers are generated, although they can be effectively separated by silica gel column chromatography. Later, we discovered that the Mitsunobu reaction can proceed smoothly when the Boc protected 2-amino group of the 2-aminopyridine moiety of **35** is further protected with a benzyl group.³⁴ In this study, we continued to use a benzyl group to protect **45a** to generate **61**. **61** was successfully converted to azide **62** by a Mitsunobu reaction (Scheme 4). Azide was chosen as the nitrogen source in the Mitsunobu reaction because the benzyl group can be removed concurrently with reduction of the azide to amine **63** when $Pd(OH)_2$ is used as the catalyst in a hydrogenation reaction. **63** was allowed to react with **56** to afford **47** by reductive amination. Compounds **16** and **26** were re-synthesized by this synthetic route.

Compound **45b** can be directly converted to **64** by a Mitsunobu reaction because the potential cyclization reaction discussed above is unfavorable for a seven-membered ring (Scheme 5). Azide **64** can be reduced to **65** with triphenylphosphine in THF and water. The reductive amination of **65** with **56** afforded **66**. The final products (**27** and **28**) were generated after standard deprotection of **66** using 4M HCl in 1,4-dioxane.

All of the above chemical structures were confirmed by 1H NMR, ^{13}C NMR, and high-resolution mass spectra as well as some by elemental analysis. All of the products are racemic mixtures.

NOS Inhibition and Structure-Activity Relationships

Table 4 shows the results of the NOS enzyme inhibition assays. None of compounds **7-14** is more potent than lead compound **6**. However, the nNOS/iNOS selectivities of **7**, **9**, and **10-12** are comparable to that of **6**, and the nNOS/eNOS selectivities of **7-9** are similar to that of **6**. The nNOS potency and selectivity of **7** is higher than those of **8** and **9**. Based on molecular docking, the dimethyl-substituted derivative (**10**) can form a H-bond interaction with the heme propionate through its amine attached to the pyrrolidine ring, and charge-charge interactions with heme propionates through the terminal tertiary amine when protonated in the active site of nNOS, just as **6** does. However, tertiary terminal amine **10** is not able to undergo H-bond interactions with heme propionate D and a conserved structural water molecule observed in the crystal structure of **6** in complex with nNOS (PDB id: 3B3N).³⁵ Based on the enzyme assay results in Table 4 these interactions appear to be important for inhibitor binding. On the other hand, conformationally-constrained molecules were designed to bind to nNOS because they can minimize the entropic penalty typically associated with binding of a flexible inhibitor and can enhance the free binding energy of the inhibitor. Compared to the dipeptide or peptidomimetic inhibitors, such as **1-5** in Table 1, some parts of the structure of **6** have been conformationally constrained.⁴ A further modification for conformational constraint was the introduction of a ring at the terminal amino group of **6**, generating **11-14**. The enzyme assay results in Table 4 show that this structural modification does not work well.

The structural modification made to target the steric and hydrophobic cavity defined by F584, P565, V567, and A566 in the S pocket was the addition of a methyl group at position 4 of the 2-aminopyridine ring of **6** to generate **15**. The nNOS potency and nNOS selectivity over eNOS of **15** quadrupled and doubled, respectively, by introduction of only one carbon atom.

The active site of nNOS contains many polar residues, cofactors, and clusters of acidic residues.²³ It is reasonable that the environment in the active site of NOS is both polar and acidic, because the natural substrate L-arginine, a polar and basic residue, needs the polar and acidic environment to stabilize it in the active site. However, the requirement of an inhibitor to bind to a polar and acidic environment raises a large problem for the design of an exogenous inhibitor that also can pass the BBB by passive absorption. The polar residues in the NOS active site require the inhibitor to contain polar functional groups, and the acidic environment requires the inhibitor to contain positively charged functional groups, which are generally inappropriate for BBB penetration. Further structural modification of **6** was directed at this problem. When **7** is docked into the active site of nNOS, Figure 5 shows that the terminal phenyl group is close to the hydrophobic cavity defined by Y706, M336, L337, and W306. A secondary amino group in **7** is more lipophilic and has less polar surface area, compared to a primary amino group.³⁶ This functional group has much better physicochemical properties for passing biomembranes than **6**, as shown in Table 5. Further structural modifications are based on the chemical structure of **7**. A molecular docking study of **7** showed that the benzyl group can adopt several different orientations in the C1 pocket because it is not long enough to form perfect interactions with the hydrophobic cavity in the C1 pocket. Two strategies were employed in the modification of the ethylenediamine side chain: (1) substituted benzyl groups were introduced at the terminal amino group of **15** to generate **16-23** in Figure 4; (2) one more carbon atom was inserted between the terminal amino group of **15** and the benzyl group to form a phenylethyl group (**24-26** in Figure 4).

Among the derivatives **16-21**, the 4-chloro substituted derivative (**16**) and the 3-chloro substituted derivative (**17**) show good inhibitory potency for nNOS. Compared to **15**, compound **16** shows twice the selectivity for nNOS over iNOS. The greater iNOS selectivity is probably triggered by the polarity difference between the corresponding residues at that site of the isozymes, rat nNOS L337 and murine iNOS N115 (human iNOS T121). The nNOS inhibition and selectivity of the dichloro-substituted analogues **22** and **23** are not as good as those of **16**, possibly due to the steric crowding. The crystal structures of **16** in complex with nNOS and eNOS have been solved. The binding conformation of **16** observed in the crystal structure of nNOS is very similar to that predicted (PDB id: 3B3O),^{23,35} and is very similar to the binding mode of dipeptide inhibitors **1**, **2**, and **4** in nNOS.²⁹

The phenylethyl-substituted derivative **24** shows higher inhibitory potency for nNOS compared to **16**. The K_i value for the racemic mixture is 24 nM and its nNOS selectivity over eNOS is over 3000 fold. The nNOS/iNOS selectivity of **24** is increased four times compared with that of **15**. That is also caused by the selectivity of residue nNOS L337 versus iNOS N115. The hydrophilicity of asparagine is incompatible with the phenyl group of **24**. The nNOS/eNOS selectivity of **24** is also increased in comparison with those of **15** and **16**. The docking mode of **24** in the active site of nNOS is shown in Figure 6A.

One potential metabolism problem of **24** is its electron-rich phenyl ring, which can be metabolized *in vivo* by cytochrome P-450 enzymes to generate the 4-hydroxyl substituted derivative, as predicted by Metasite 2.5.3.³⁹ The introduction of a halogen atom at position 4 of the ring will help the metabolic stability. Computer modeling shows that the enzyme at position 4 of the bound compound is not large enough to accommodate even a fluorine atom. The superimposition of the docking conformations of **25** and **26** clearly shows that the ethylenediamine side chain of **25** has to adopt a curled conformation to accommodate its 4-

fluorophenyl group into the hydrophobic cavity defined by Y706, L337, M336, and W306 (Figure 6B). However, position 3 of the phenyl group contains an extra small pocket defined by L337 and Y706, which is appropriate for a fluorine atom. The result of the NOS inhibitory activity assay (Table 4) confirms that **26** is a better nNOS inhibitor than **25**. The nNOS/eNOS selectivity of **26** is also much better than that of **25**. Compared to **25**, **26** might be a little more vulnerable to metabolism, but it is much more stable than **24**.

Compounds **27** and **28** are the 2-amino-6-methylpyridino analogues of **16** and **26**, respectively. The NOS enzyme assay shows that the nNOS inhibitory activities and selectivities are decreased dramatically in **27** and **28**. Compared to **16** and **26**, the 6-methyl groups of **27** and **28** can form van der Waals contacts with the hydrophobic cavity defined by F584, P565, V567, and A566 in the S pocket, and the 2-amino group can also form H-bond interactions with the backbone amide of W587. A more than 200-fold drop in inhibitory potency in comparing **27** with **16** suggests that the charge-charge and H-bond interactions between the protonated pyridine nitrogen atom and E592 are important for the binding of this series of inhibitors with nNOS.

To provide inhibitors with better biomembrane permeability, methylation of one of two amino groups of the ethylenediamine side chain of **16** and **26** to generate compounds **30-32** was carried out. Compound **30** is the methylated derivative of **16**. The nNOS potency is decreased four-fold, while the nNOS/eNOS and nNOS/iNOS selectivities are decreased three-fold and two-fold, respectively. The nNOS inhibitory activities and nNOS selectivities of **31** and **32** are decreased dramatically compared to those of **26**, although they have improved physicochemical properties for biomembrane penetration. Compound **29** was designed to increase lipophilicity (see Table 5) by introduction of an alkyl group on the carbon atom adjacent to the amino group. The nNOS inhibition of **29** is comparable to that of **16**. However, the selectivity between nNOS and eNOS is decreased by three fold, while the selectivity between nNOS and iNOS is maintained.

Conclusion

This study of structure-activity relationships of 2-aminopyridine analogues demonstrates that a significant improvement in nNOS inhibitory activity, nNOS/eNOS selectivity, and physicochemical/pharmacokinetic properties can be achieved by our structure-based de novo design strategy, *fragment hopping*. Using the extracted minimal pharmacophoric elements for hydrophobic and steric interactions, fragments were generated from focused fragment libraries, and lead compound **6** was evolved into high potent and selective inhibitors with better drug-like properties. Two hydrophobic/steric pockets that were identified by fragment hopping were verified by inhibitor design.

Halogen-substituted phenyl fragments were introduced at the terminal amino group of the ethylenediamine fragment for three reasons: (1) The phenyl group can be stabilized in a hydrophobic pocket defined by M336, L337, Y706, and W306. The residues that correspond to rat nNOS L337 are N115 in murine iNOS and T121 in human iNOS, respectively. Therefore, the hydrophobic aryl group could be used to differentiate the hydrophobic L337 in nNOS from the polar N115 and T121 residues in murine and human iNOS, respectively. (2) The introduction of the phenylalkyl group renders the amino group of the ethylenediamine fragment a secondary amine and decreases its polar surface area, which is favorable for biomembrane permeability, compared to the primary amino group in **6**.³⁶ (3) The introduction of a halogen atom at the para or meta positions of the phenyl group blocks/decreases the potential for metabolic degradation of the phenyl group as well as increases its lipophilicity. Compounds **16** and **26**, which are the best of the substituted benzyl and substituted phenethyl derivatives, respectively, were tested in a rabbit model for cerebral palsy and found to prevent hypoxia-

ischemia induced deaths and to reduce the number of newborn kits exhibiting symptoms of cerebral palsy.²³ Following maternal administration in a rabbit model, these two compounds were found to distribute to fetal brain, to be non-toxic, without cardiovascular effects, inhibit fetal brain NOS activity *in vivo* and dramatically ameliorate deaths and the number of newborn kits exhibiting signs of cerebral palsy without affecting the eNOS regulated blood pressure.²³

In a previous study⁴ we demonstrated that fragment hopping can be used to generate a series of new inhibitors with different chemical structures. This study demonstrates that fragment hopping also can facilitate a structural optimization process. Greater inhibitory potency, isozyme selectivity, and improved drug-like properties can be achieved by a couple rounds of substitution of multiple functionality or cores onto a single high-affinity lead. The structure-activity relationship analysis matched the extracted pharmacophoric elements. The robustness and efficiency of fragment hopping in these studies show that it can be widely applicable to expedite the lead discovery and structural optimization efforts for many other targets for which known small molecule modulators are limited.

Recently, a crystallography-based approach for the design of selective iNOS inhibitors called anchored plasticity was reported.⁴⁰ The general idea is that the “head” of the inhibitor binds directly over the heme, where it is anchored in place by the isozyme-invariant Glu residue. The “tail” of the inhibitor then extends out of the active site, where subtle differences in the NOS isoforms lead to isoform selectivity. This is basically the same approach we took in our earlier studies using nitroarginine as the anchor for the design of nNOS-selective inhibitors, which became the basis for fragment hopping.⁴¹ However, unlike fragment hopping, in the anchored plasticity model, conformational changes, which involve residues that both directly contact the bulky tail of the inhibitor as well as second and third tier amino acids, are required to control isoform selectivity. Some key third tier amino acids that differ between eNOS and iNOS were shown to be critical in controlling greater potency in iNOS inhibition compared to eNOS. Although the two approaches share common features, there are distinct differences. Unlike anchored plasticity, our fragment hopping approach does not require prior identification of isozyme-selective inhibitors. The minimal pharmacophoric elements for ligand isozyme selectivity can be derived directly by comparison of the isozyme structures with the use of the GRID/CPCA approach. Another difference is that anchored plasticity requires the crystallographic determination of isoform-selective conformational changes while this is not the case with fragment hopping.

Experimental Section

Computer Modeling

Protein Structures—The crystallographic coordinates for NOS from the Research Collaboratory for Structural Bioinformatics (RCSB) protein database are as follows: rat nNOS1: 1P6I (1.90 Å resolution, R_{cryst} = 0.228); 3B3N (1.98 Å resolution, R_{cryst} = 0.230). The amino acid sequences of NOS were retrieved from the PIR protein sequence database. The sequences are human nNOS (entry P29475), rat nNOS (entry P29476), human eNOS (entry P29474), bovine eNOS (entry P29473), human iNOS (entry P35228), and murine iNOS (entry P29477). All of the computational work was performed on Silicon Graphics Octane 2 Workstations with an IRIX 6.5 operating system. The molecular modeling was achieved with commercially available InsightII 2000⁴² and SYBYL 6.8⁴³ software packages. The NOS model was prepared by first adding H-atoms using the Accelrys/InsightII 2000 software, and the protonation states of the residues were set to pH 7.0. The cvff force field of the Discover 98.0 program within Insight II was used to optimize the orientation of hydrogen atoms of the protein and of structural waters. The ligands and solvent molecules of the protein structures were removed, but the heme and H₄B were retained near the active site.

GRID Calculations—The calculations were performed with version 22 of the GRID software.⁴⁴ Hydrogens were added with the program GRIN. The GRID box dimensions were chosen to encompass all of the active site residues. This resulted in a box size of $31 \times 28 \times 31$ Å. The grid spacings were set to 1 Å (directive NPLA = 1) and 0.5 Å (directive NPLA = 2), respectively. The amino acids in the active site were considered rigid (directive move = 0). The directives NETA and ALMD were set to 120 and 1, respectively, to include the atoms of heme and H₄B in calculations and to interpret which atom(s) in the active site contribute(s) to the interaction with a specific probe atom. The following single atom probes were used in the calculation: DRY, C3, C1=, NM3, N1+, N2+, Cl and F.

MCSS Calculations—The functional groups chosen for the MCSS calculations were benzene (all hydrogen model), cyclohexane, isobutene, n-butane, propane, trimethylamine cation, and dimethylamine cation. The binding site area in the MCSS simulation was defined as an approximately $27 \text{ Å} \times 26 \text{ Å} \times 31 \text{ Å}$ box. Replicas of a given functional group were randomly distributed inside the binding site and then simultaneously and independently energy minimized. Pairs of molecules were considered to be identical if the root-mean-square deviation (RMSD) between them was less than 0.2 Å, and in such cases one of the pairs was eliminated. The above protocol was repeated 10 times for each of the functional groups to allow complete searching of the active site. The minima with the binding energy lower than 0 kcal/mol were retrieved in the analysis. All of the above calculations were performed using the CHARMM 22 force field and the MCSS 2.1 program.⁴⁵

LUDI Ligand Design—LUDI³³ was first applied to generate the interaction sites for each pharmacophore. The residues inside an 8.0 Å radius sphere, which centered on the centroid of the minimal pharmacophoric elements, were used to generate the interaction sites. The link library switch was turned off, and the target mode switch was turned on. The LUDI scoring function was set to Energy-estimate-2.⁴⁶ Other settings were kept with the standard default parameters. To convert the above determined fragments into a molecule, the LUDI link library was used in the connection operation. The hydrogen atoms in the above fragment structure were replaced by a link fragment to create a new compound. The switch for the target mode was turned off, but the switch for the link library was turned on. The linkage parameter can be set to 1 (the link fragment fit at least one link site), 2 (the link fragment simultaneously fit at least two link sites), or be specified (the link site was specifically assigned) according to the actual requirements. The other settings are the standard default parameters.

AutoDock Analysis—AutoDock 3.0.5 was employed to perform the docking calculations.⁴⁷ For the protein structure (PDB id: 1P6I), polar hydrogen atoms were added, and Kollman united atom charges were assigned.⁴⁸ Hydrogens were also added to the heme and H₄B, and charges were calculated by the Gasteiger-Marsili method.⁴⁹ The charge of the Fe atom bound to heme was assigned +3. The nonpolar hydrogen atoms of heme and H₄B were removed manually, and their charges were united with the bonded carbon atoms. Atomic solvation parameters and fragmental volumes were assigned using the AddSol utility. The 3D structures of the ligands were built and partial atomic charges were also calculated using the Gasteiger-Marsili method. The rotatable bonds in the ligands were defined using another AutoDock 3.0 auxiliary program, AutoTors, which also unites the nonpolar hydrogens and partial atomic charges to the bonded carbon atoms. The grid maps were calculated using AutoGrid. The dimensions of the grid box was $27 \times 26 \times 31$ Å, and the grid spacing was set to 0.375 Å. Docking was performed using the Lamarckian genetic algorithm (LGA), and the pseudo-Solis and Wets method were applied for the local search. The procedure in detail used was that previously described.^{4,30}

Chemical Synthesis

General Methods, Reagents and Materials—All reagents were purchased from Aldrich, Acros Organics, or Fisher Scientific and were used without further purification unless stated otherwise. NADPH, calmodulin, and human ferrous hemoglobin were obtained from Sigma Chemical Co. Tetrahydrobiopterin (H₄B) was purchased from Alexis Biochemicals. ¹H NMR and ¹³C NMR spectra were recorded on a Varian Mercury 400 MHz or a Varian Inova 500 MHz spectrometer (100.6, or 125.7 MHz, for ¹³C NMR spectra, respectively) in CDCl₃, DMSO-*d*₆, CD₃OD or D₂O. Chemical shifts are reported as values in parts per million and the reference resonance peaks set at 0 ppm [TMS(CDCl₃)], 2.50 ppm [(CD₂H)₂SO], 3.31 ppm (CD₂HOD), and 4.80 ppm (HOD) respectively for ¹H NMR and 77.23 ppm (CDCl₃), 39.52 ppm (DMSO-*d*₆) and 49.00 ppm (CD₃OD) for ¹³C NMR spectra. An Orion research model 701H pH meter with a general combination electrode was used for pH measurements. Mass spectra were performed on a Micromass Quattro II triple quadrupole HPLC/MS mass spectrometer with an electrospray ionization (ESI) source or atmospheric pressure chemical ionization (APCI) source. High-resolution mass spectra were carried out using a VG70-250SE mass spectrometer. Chemical ionization (CI) or electron impact (EI) was used as the ion source. Elemental analyses were performed by Atlantic Microlab Inc., Norcross, GA. Thin-layer chromatography was carried out on E. Merck pre-coated silica gel 60 F254 plates with visualization accomplished with phosphomolybdic acid or ninhydrin spray reagent or with a UV-visible lamp. Column chromatography was performed with E. Merck silica gel 60 (230-400 mesh) or Sorbent Technologies 250 mesh silica gel. Tetrahydrofuran (THF) and ethyl ether were redistilled under nitrogen using sodium and benzophenone as the indicator. Dichloromethane was redistilled from CaH₂ under nitrogen. Other dry solvents were directly purchased from the companies. *N*¹, *N*¹-dimethylethane-1,2-diamine, (*S*)-(-)-1-Boc-3-aminopyrrolidine, (*R*)-(+)-1-Boc-3-aminopyrrolidine, (*S*)-(+)-1-benzyl-3-aminopyrrolidine, (*R*)-(-)-1-benzyl-3-aminopyrrolidine, and *N*-Boc-1,2-diaminoethane were purchased from Aldrich.

(±)-*cis*-*tert*-Butyl 3-{2'-[benzyl(*tert*-butoxycarbonyl)amino]ethylamino}-4-{[6'-(*tert*-butoxycarbonylamino)pyridin-2'-yl]methyl}pyrrolidine-1-carboxylate (37a)—A mixture of **36** (0.196 g, 0.5 mmol),⁴ a substituted amine such as **41** (0.138 g, 0.55 mmol), sodium triacetoxyborohydride [NaBH(OAc)₃] (0.149 g, 0.7 mmol), and 3 Å molecular sieves (0.5 g) in dry 1,2-dichloroethane (10 mL) was stirred at room temperature under a nitrogen atmosphere for 14 h (TLC used to monitor the completion of the reaction). To the reaction mixture was then added 1 M NaOH (15 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (15 mL × 2). The combined organic layers were washed with brine (20 mL) and dried over MgSO₄. The solvent was concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9 : 1 : 0.5) to afford a pale-yellow oil (0.199 g, 85%, diastereomer ratio: *cis* : *trans* = 75 : 25). ¹H NMR (CDCl₃, 500 MHz): δ 7.783-7.748 (m, 1H), 7.556-7.512 (m, 1H), 7.337-7.234 (m, 6H), 6.798-6.775 (m, 1H), 4.569-4.438 (m, 2H), 3.340-3.109 (m, 7H), 2.774-2.573 (m, 5H), 1.506-1.454 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (158.450+158.318) (1C), (154.856+154.775) (1C), (152.844+152.763) (1C), (151.974+151.834) (1C), (138.761+138.684) (1C), (138.808+138.781) (1C), 128.525 (2C), 127.947 (1C), 127.247 (2C), (117.685+117.484) (1C), (109.870+109.789) (1C), 80.716 (1C), (80.108+79.986) (1C), 79.184 (1C), (59.569+58.594) (1C), (50.869+50.362) (1C), (50.686+50.182) (1C), (49.731+49.398) (1C), (48.191+48.157) (1C), (46.267+46.220) (1C), (42.514+41.462) (1C), (35.045+34.983) (1C), 28.658 (3C), 28.426 (3C), 28.264 (3C). MS (ESI, CH₃OH): [C₃₄H₅₁N₅O₆] *m/z* 626.5 ([M+H]⁺).

***N*¹-{[(±)-4'-[(6''-aminopyridin-2''-yl)methyl]pyrrolidin-3'-yl]-*N*²-benzylethane-1,2-diamine tetrachloride (7)}**—A solution of 4M HCl in 1,4-dioxane (4 mL) was added to **37a** (0.125 g, 0.2 mmol) at 0 °C under an argon atmosphere. The ice-water bath was removed

after 3 h, and the reaction mixture was stirred at room temperature for 36 h. After the completion of the reaction, liquids were evaporated under reduced pressure, and the residue was partitioned between water (10 mL) and ethyl acetate (10 mL). The aqueous layer was then washed with ethyl acetate (5 mL \times 2). After evaporation of water by high-vacuum rotory evaporation, the residue was dried with a lyophilizer to afford a hygroscopic white solid (0.0943 g, quantitative yield). ^1H NMR (D_2O , 500 MHz): δ 7.843 (t, 1H, $J=9\text{Hz}$), 7.544-7.516 (m, 5H), 7.063 (d, 1H, $J=9\text{Hz}$), 6.8235 (d, 1H, $J=6.5\text{Hz}$), 4.344 (s, 2H), 4.287-4.089 (m, 1H), 3.895-3.785 (m, 1H), 3.750-3.154 (m, 9H), 2.914-2.849 (m, 1H). ^{13}C NMR (D_2O , 125.7 MHz): δ 154.843 (1C), 144.819 (2C), 130.238 (1C), 130.114 (1C), 130.041 (2C), 129.542 (2C), 112.535 (2C), 58.524 (1C), 51.831 (1C), 47.475 (1C), 46.005 (1C), 43.324 (2C), 38.964 (1C), 29.369 (1C). MS (ESI, CH_3OH): $[\text{C}_{19}\text{H}_{27}\text{N}_5]$ m/z 326.3 ($[\text{M}+\text{H}]^+$). HRMS (CI^+ , CH_3OH) Calc.: 326.2339, Found: 326.2334. Comb. Anal. ($\text{C}_{19}\text{H}_{27}\text{N}_5 \cdot 4\text{HCl} \cdot 1.75\text{H}_2\text{O}$), Calcd: C, 45.39; H, 6.92; N, 13.93, Found: C, 45.38; H, 6.78; N, 13.66.

tert-Butyl benzyl(2-hydroxyethyl)carbamate (38)—A solution of di-*tert*-butyl dicarbonate (1.094 g, 0.005 mol) in CH_2Cl_2 (20 mL) was added dropwise to a solution of 2, benzylaminoethanol (0.756 g, 0.005 mol) in CH_2Cl_2 (20 mL) and 1M NaOH (16 mL). The reaction mixture was then stirred at room temperature for 24 h, and the organic layer was separated. The aqueous layer was extracted with CH_2Cl_2 (10 mL \times 2). The combined organic layers were washed with water (10 mL \times 2) and dried over Na_2SO_4 . The solvent was evaporated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes : EtOAc = 7 : 3) to afford a colorless oil (1.256 g, quantitative yield). ^1H NMR (CDCl_3 , 500 MHz): δ 7.339-7.234 (m, 5H), 4.474 (m, 2H), 3.693 (m, 2H), 3.399 (m, 2H), 1.459 (s, 9H). ^{13}C NMR (CDCl_3 , 125.7 MHz): δ 154.500 (1C), 138.366 (1C), 128.733 (1C), 127.453 (2C), 127.329 (1C), 80.743 (1C), (62.227+61.334) (1C), (52.184+51.155) (1C), (49.956+49.113) (1C), 28.535 (3C). MS (ESI, CH_3OH): $[\text{C}_{14}\text{H}_{21}\text{NO}_3]$ m/z 252.3 ($[\text{M}+\text{H}]^+$); m/z 274.4 ($[\text{M}+\text{Na}]^+$); m/z 525.0 ($[\text{2M}+\text{Na}]^+$).

tert-Butyl 2-aminoethyl(benzyl)carbamate (41)—To a solution of triphenylphosphine (Ph_3P , 1.64 g, 0.00625 mol) in dry THF (10 mL) was added **38** (1.256 g, 0.005 mol) in dry THF (10 mL) at 0 °C under a N_2 atmosphere *via* a cannula. Diisopropyl azodicarboxylate (DIAD, 1.315 g, 1.30 mL, 0.0065 mol) was added dropwise, and the solution was stirred for 20 min at 0 °C. Diphenylphosphoryl azide (DPPA, 1.72 g, 1.347 mL, 0.00625 mol) was added at 0 °C, and the solution was stirred overnight at room temperature. The reaction mixture was then concentrated *in vacuo*. The crude residue was purified by column chromatography (silica gel, hexanes : EtOAc = 9.5 : 0.5) to yield a colorless oil.

The above azide product was dissolved in THF (5 mL) and was put into an ice-cold bath, then Ph_3P (1.574 g, 0.006 mol) and H_2O (0.324 g, 0.018 mol) were added at 0 °C. The reaction mixture was stirred for 2 h at 0 °C and for 21 h at room temperature. The solvent was evaporated *in vacuo*, and the residue was partitioned between water (10 mL) and CH_2Cl_2 (10 mL). The aqueous layer was extracted with CH_2Cl_2 (10 mL \times 2). The combined organic layers were dried over MgSO_4 , and the solvent was evaporated *in vacuo*. The residue was purified by column chromatography (silica gel, CH_2Cl_2 : MeOH = 9 : 1) to afford a colorless oil (0.751 g, 60%). ^1H NMR (CDCl_3 , 500 MHz): δ 7.334-7.238 (m, 5H), 4.464 (m, 2H), 3.289-3.204 (m, 2H), 2.782 (m, 2H), 1.456 (s, 9H), 1.049 (brs, 2H). ^{13}C NMR (CDCl_3 , 125.7 MHz): δ 156.268 (1C), 138.607 (1C), 128.688 (2C), 127.860 (1C), 127.368 (2C), 80.027 (1C), (51.294+50.737) (1C), 50.118 (1C), 40.628 (1C), 28.596 (3C). MS (ESI, CH_2Cl_2): $[\text{C}_{14}\text{H}_{22}\text{N}_2\text{O}_2]$ m/z 251.2 ($[\text{M}+\text{H}]^+$), 501.0 ($[\text{2M}+\text{H}]^+$).

The amine product can also be prepared by hydrogenation of the azide. The azide product was dissolved in MeOH (15 mL), and to the reaction solution was added a catalytic amount of 10% Pd/C. The solution was stirred under a H_2 atmosphere at room temperature for 24h. The solution

was then filtered through Celite, and the Celite pad was washed with MeOH (10 mL \times 2). The combined filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica gel, CH₂Cl₂ : MeOH = 9 : 1) to afford a colorless oil (0.688 g, 55%).

(±)-*tert*-Butyl 3-[[6'-(*tert*-butoxycarbonylamino)-4'-methylpyridin-2'-yl]methyl]-4-[2'-(*tert*-butoxycarbonylamino)ethylamino]pyrrolidine-1-carboxylate (47a)—A mixture of **46** (0.203 g, 0.5 mmol), ²³N-Boc-1,2-diaminoethane (0.089 g, 0.55 mol), NaBH(OAc)₃ (0.149 g, 0.7 mmol), and 3 Å molecular sieves (0.5 g) in dry 1,2-dichloroethane (10 mL) was stirred at room temperature under a N₂ atmosphere for 16 h. The reaction mixture was then filtered through Celite, and the Celite pad was washed with CH₂Cl₂ (5 mL \times 2). To the filtrate was added 1M NaOH (10 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (10 mL \times 2). The combined organic layers were washed with brine (10 mL) and dried over MgSO₄. The solvent was evaporated, and the residue was purified by column chromatography (silica gel, hexane: EtOAc : Et₃N = 6: 4: 0.25) to afford a colorless oil (0.196 g, 95%, diastereomer ratio: *cis* : *trans* = 75 : 25). ¹H NMR (CDCl₃, 500 MHz): δ 7.635-7.622 (s, 1H), 7.373 (m, 1H), 6.657 (s, 1H), 5.451 (brs, 1H), 3.444-3.346 (m, 3H), 3.224-3.076 (m, 4H), 2.863-2.803 (m, 2H), 2.588-2.562 (m, 3H), 2.321-2.299 (m, 3H), 1.523 (s, 9H), 1.455 (s, 18H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 158.521 (1C), 156.374 (1C), (155.035+154.973) (1C), 152.706 (1C), 151.670 (1C), 150.126 (1C), 119.280 (1C), 110.498 (1C), 81.006 (1C), 79.408 (2C), (59.023+57.913) (1C), (51.007+50.640) (1C), (49.526+49.228) (1C), 47.436 (1C), (42.941+42.125) (1C), 40.623 (1C), (35.099+35.006) (1C), 28.680 (3C), 28.595 (3C), 28.468 (3C), 21.465 (1C). MS (ESI, CH₃OH): [C₂₈H₄₇N₅O₆] *m/z* 550.4 ([M+H]⁺).

2-(3'-chlorobenzylamino)ethanol (48a)—3-Chlorobenzaldehyde (1.4 g, 0.01 mol) was dissolved in dry ethanol (30 mL), and ethanolamine (0.61 g, 0.01 mol) was added. The reaction mixture was stirred overnight at 60 °C. The ethanol was evaporated under reduced pressure to give a colorless oil. The oil was then dissolved in dry methanol (30 mL) and cooled in ice. Sodium borohydride (NaBH₄, 0.57g, 0.015 mol) was added slowly in portions, and the resulting solution was left overnight at room temperature. The solvent was evaporated *in vacuo*, and the residue was dissolved in water and extracted with CH₂Cl₂ (3 \times 20 mL). The organic layers were combined and dried with Na₂SO₄, filtered and evaporated *in vacuo*. The residue was purified by column chromatography (silica gel, CH₂Cl₂ : MeOH = 9.5 : 0.5) to generate a pale-green oil (1.795 g, 97%). ¹H NMR (CDCl₃, 500 MHz): δ 7.322 (m, 1H), 7.271-7.221 (m, 2H), 7.199-7.186 (m, 1H), 3.785 (s, 2H), 3.662 (t, 2H, J=5.5Hz), 2.788 (t, 2H, J=5.5Hz), 2.079 (brs, 2H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 142.374 (1C), 134.513 (1C), 129.919 (1C), 128.378 (1C), 127.439 (1C), 126.388 (1C), 61.200 (1C), 53.155 (1C), 50.731 (1C). MS (ESI, CH₃OH): [C₉H₁₂ClNO] *m/z* 186.5 ([M+H]⁺); *m/z* 371.2 ([2M+H]⁺).

2-(4'-fluorophenyl)acetaldehyde (49a)—To a suspension of Dess-Martin periodinane (2.04 g, 0.0048 mol) in anhydrous CH₂Cl₂ (50 mL) was added dropwise 4-fluorophenethyl alcohol (0.56 g, 0.5 mL, 0.004 mol). The reaction mixture was stirred at room temperature for 16 h under a N₂ atmosphere. Na₂S₂O₃ (1M, 40 mL) was then added to the reaction mixture, and after being stirred for 15 min, the mixture was separated. The aqueous layer was extracted with CH₂Cl₂ (20 mL \times 2). The combined organic layers were washed with 5% NaHCO₃ (20 mL \times 2) and brine (10 mL) and dried over Na₂SO₄. The solvent was concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes : EtOAc = 8 : 2) to afford a pale-yellow volatile oil (0.437, 79%). ¹H NMR (CDCl₃, 500 MHz): δ 9.747-9.743 (m, 1H), 7.195-7.167 (m, 2H), 7.076-7.041 (m, 2H), 3.683 (s, 2H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 199.225 (1C), (163.354+161.393) (1C), (131.394+131.327) (2C), (127.721+127.696) (1C), (116.154+115.984) (2C), 49.823 (1C).

2-[benzyl(phenethyl)amino]ethanol (50a)—A mixture of commercially-available phenylacetaldehyde (90%, 0.40 g, 0.003 mol), *N*-benzylethanolamine (0.5 g, 0.0033 mol), and NaBH(OAc)₃ (0.90 g, 0.0042 mol) in dry 1,2-dichloroethane (60 mL) was stirred at room temperature under a N₂ atmosphere for 14 h. To the reaction mixture was then added 1M NaOH (40 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (30 mL × 2). The combined organic layers were washed with brine (20 mL) and dried over MgSO₄. The solvent was concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes : EtOAc = 5 : 5) to afford a pale-yellow oil (0.766 g, quantitative yield). ¹H NMR (CDCl₃, 500 MHz): δ 7.289-7.105 (m, 10H), 3.675 (s, 2H), 3.509 (m, 2H), 2.766 (m, 4H)-2.673 (t, 2H, J=5Hz), 2.559 (brs, 1H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 140.240(1C), 138.898 (1C), 129.020(2C), 128.850 (2C), 128.552 (1C), 128.528 (1C), 127.302 (1C), 126.239 (1C), 58.627 (1C), 58.390 (1C), 55.306 (1C), 55.251 (1C), 33.624 (1C). MS (ESI, CH₃OH): [C₁₇H₂₁NO] *m/z* 256.4 ([M+H]⁺); *m/z* 272.2 ([M+Na]⁺).

2-(phenethylamino)ethanol (51a)—A suspension of 50a (0.766 g, 0.003 mol) and 10% Pd/C (450 mg) in MeOH (30 mL) was stirred at room temperature under a hydrogen atmosphere overnight. The catalyst was then filtered through Celite. The Celite pad was washed with MeOH (10 mL × 3), and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, CH₂Cl₂ : MeOH = 8.5 : 1.5) to yield a pale-green oil (0.382 g, 77%). ¹H NMR (CDCl₃, 500 MHz): δ 7.309-7.199 (m, 5H), 3.663 (t, 2H, J=5Hz), 2.931 (t, 2H, J=7Hz), 2.849 (t, 2H, J=7Hz), 2.818 (t, 2H, J=4.5Hz), 3.194 (brs, 2H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 139.493 (1C), 128.868 (2C), 128.735 (2C), 126.850 (1C), 60.467 (1C), 51.086 (1C), 50.685 (1C), 35.956 (1C). MS (ESI, CH₃CN): [C₁₀H₁₅NO] *m/z* 166.4 ([M+H]⁺).

(±)-tert-Butyl 3-{{2'-[tert-butoxycarbonyl(4"-chlorobenzyl)amino]ethyl}(methyl)amino}-4-[[6'-(tert-butoxycarbonylamino)-4'-methylpyridin-2'-yl]methyl]pyrrolidine-1-carboxylate (54a or 55a)—To a solution of 47b 0.337 g, 0.5 mmol) dissolved in MeOH (10 mL) at 0 °C was added a 37% formaldehyde solution (0.405 g, 0.375 mL, 0.005 mol), sodium cyanoborohydride [NaBH₃CN (0.165 g, 0.0025 mol)], and acetic acid (0.06 g, 0.06 mL, 0.001 mol). The reaction mixture was then stirred at room temperature overnight. The solvent was removed under reduced pressure. The residue was dissolved in water, extracted with CH₂Cl₂ (10 mL × 3). The combined organic layers were dried over anhydrous MgSO₄, and evaporated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes : EtOAc = 6 : 4) to generate a colorless oil (54a, 0.325 g, 94%). ¹H NMR (CDCl₃, 500 MHz): δ 7.594-7.579 (m, 1H), 7.288-7.266 (m, 2H), 7.178-7.152 (m, 3H), 6.664-6.613 (s, 1H), 4.522-4.401 (m, 2H), 3.614-3.522 (m, 1H), 3.418-3.078 (m, 5H), 2.953-2.838 (m, 2H), 2.695-2.516 (m, 2H), 2.474-2.170 (m, 8H), 1.518-1.389 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (159.189+159.068+158.928) (1C), (155.929+155.528) (1C), (155.006+154.903) (1C), 152.547 (1C), 151.521 (1C), (149.882+149.791) (1C), (137.320+137.071) (1C), 133.112 (1C), (129.226+128.807+128.540) (4C), (119.919+119.822) (1C), 110.095 (1C), (80.921+80.830) (1C), 80.114 (1C), 79.391 (1C), (66.429+65.797) (1C), (54.104+53.752) (1C), (50.965+50.643+50.260+49.872) (1C), (49.775+49.338) (1C), (48.743+48.396) (1C), (44.201+44.007) (1C), (40.631+40.285+39.902) (2C), 33.898 (1C), (28.707+28.652+28.561+28.415) (9C), 21.415 (1C). MS (ESI, CH₃OH): [C₃₆H₅₄ClN₅O₆] *m/z* 688.5 ([M+H]⁺).

The title compound can also be made by the following synthetic route: To a solution of 46 (0.203 g, 0.5 mmol), 57a (0.149 g, 0.5 mmol), acetic acid (0.045 g, 0.043 mL, 0.75 mmol), and 3 Å molecular sieves (0.5 g) in dry MeOH (5 mL) was added NaBH₃CN (0.063 g, 0.001 mol). The reaction mixture was stirred at room temperature under a N₂ atmosphere for 36 h (TLC monitor the completion of reaction). The reaction mixture was then filtered. The filtrate

was concentrated in vacuo, and the residue was diluted with 1M NaOH (15 mL), extracted with CH₂Cl₂ (15 mL × 2). The organic layers were washed with brine, dried over anhydrous MgSO₄, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexanes : EtOAc = 6 : 4) to produce a colorless oil (**55a**, 0.327 g, 95%).

tert-Butyl 4-chlorobenzyl(2'-oxoethyl)carbamate (56a)—To a suspension of Dess-Martin periodinane (0.509 g, 0.0012 mol) in anhydrous CH₂Cl₂ (10 mL) was added a solution of **52b** (0.285 g, 0.001 mol) in anhydrous CH₂Cl₂ (5 mL). Then the reaction mixture was stirred at room temperature for 21 h under a N₂ atmosphere. Na₂S₂O₃ (1 M, 10 mL) was added to the reaction mixture, and after stirring for 10 min, the reaction mixture was extracted with CH₂Cl₂ (10 mL × 3). The combined organic layers were washed with 5% aqueous NaHCO₃ (20 mL) and brine (20 mL). The organic layer was dried over Na₂SO₄ and evaporated *in vacuo*. The residue was then purified by column chromatography (silica gel, hexanes : EtOAc = 8 : 2) to afford a colorless oil (0.20 g, 72%). ¹H NMR (CDCl₃, 500 MHz): δ (9.492+9.430) (s, 1H), 7.294 (m, 2H), 7.196-7.154 (m, 2H), 4.489-4.451 (m, 2H), 3.938 (m, 1H), 3.798 (m, 1H), 1.465 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (198.988+198.897+198.502+198.405+197.998) (1C), (155.783+155.510) (1C), (136.063+135.905) (1C), (133.671+133.567) (1C), (129.585+129.038+128.971) (4C), 81.371 (1C), 56.684 (1C), (51.560+51.068) (1C), (28.421+28.330) (3C).

tert-Butyl 4-chlorobenzyl[2'-(methylamino)ethyl]carbamate (57a)—To a solution of **56a** (0.566 g, 0.002 mol) in MeOH (30 mL) was added MeNH₂ (2M in MeOH, 2 mL, 0.004 mol) at room temperature under a N₂ atmosphere. The reaction mixture was heated at reflux for 6 h and then cooled to -20 °C. Then NaBH₄ (0.15 g, 0.004 mol) was added in portions. After being stirred for 1 h at -20 °C, the reaction mixture was stirred for 3 h at room temperature. The solvent was then evaporated under reduced pressure. The residue was dissolved in water (20 mL) and extracted with CH₂Cl₂ (20 mL × 3). The combined organic layers were washed with brine and dried over MgSO₄. The solvent was evaporated *in vacuo*, and the residue was purified by column chromatography (silica gel, CH₂Cl₂ : MeOH = 9:1) to afford a colorless oil (0.59 g, 99%). ¹H NMR (CDCl₃, 500 MHz): δ 7.287 (d, 2H), 7.174 (m, 2H), 4.428 (s, 2H), 3.348-3.260 (m, 2H), 2.710 (m, 2H), 2.412 (s, 3H), 1.568-1.444 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 155.993 (1C), 137.216 (1C), 133.076 (1C), (129.220+128.795+128.577) (4C), 80.241 (1C), (50.825+50.115) (2C), 46.551 (1C), 36.423 (1C), 28.567 (3C). MS (ESI, CH₂Cl₂): [C₁₅H₂₃ClN₂O₂] *m/z* 299.1 ([M+H]⁺).

tert-Butyl methyl[2-(methylamino)ethyl]carbamate (58)—A solution of di-*tert*-butyl dicarbonate (2.183 g, 0.01 mol) in CH₂Cl₂ (120 mL) was added dropwise to a solution of *N,N'*-dimethylethane-1,2-diamine (1.763 g, 0.02 mol) in CH₂Cl₂ (40 mL) over 6 h with vigorous stirring. The reaction mixture was stirred for an additional 18 h at room temperature. Then the solvent was concentrated *in vacuo* to give an oily residue, which was dissolved in 60 mL of 2 M aqueous Na₂CO₃ and extracted with CH₂Cl₂ (30 mL × 2). The combined organic layers were washed with 2 M Na₂CO₃ (30 mL × 2) and dried over anhydrous MgSO₄. The solvent was evaporated *in vacuo* to yield the product, which was purified by column chromatography (silica gel, CH₂Cl₂ : MeOH, 9:1) to afford a colorless oil (1.15 g, 61%). ¹H NMR (CDCl₃, 500 MHz): δ 3.347 (m, 2H), 2.893-2.882 (m, 3H), 2.744-2.734 (m, 2H), 2.466-2.452 (m, 3H), 1.625 (brs, 1H), 1.474-1.459 (m, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 156.014 (1C), 79.452 (1C), 49.720 (1C), (48.475+48.202) (1C), 36.308 (1C), 34.632 (1C), 28.452 (1C). MS (ESI, CH₃OH): [C₉H₂₀N₂O₂] *m/z* 189.2 ([M+H]⁺); *m/z* 377.3 ([2M+H]⁺).

tert-Butyl 2-[(3'-fluorophenethyl)(methyl)amino]ethyl(methyl)carbamate (59a)—A mixture of **58** (0.941 g, 0.005 mol), 3-fluoro-phenyl-acetaldehyde (0.76 g, 0.0055 mol), and NaBH(OAc)₃ (1.48 g, 0.007 mol) in dry 1,2-dichloroethane (50 mL) was stirred overnight at

room temperature under a N₂ atmosphere. To the reaction mixture was added 1 M NaOH (30 mL), and then the mixture was extracted with CH₂Cl₂ (30 mL × 3). The combined organic layers were washed with brine and dried over MgSO₄. The solvent was then evaporated *in vacuo* to give the product, which was purified by column chromatography (silica gel, hexanes : EtOAc = 5:5) to afford a colorless oil (1.0 g, 65%). ¹H NMR (CDCl₃, 500 MHz): δ 7.235-7.222 (m, 1H), 6.975-6.960 (m, 1H), 6.915-6.862 (m, 2H), 3.322-3.277 (m, 2H), 2.856-2.831 (m, 3H), 2.771-2.740 (t, 2H, J=7 Hz), 2.652-2.621 (t, 2H, J=7.5 Hz), 2.546 (m, 2H), 2.330 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (163.937+161.982) (1C), 155.765 (1C), 143.063 (1C), 129.840 (1C), 124.491 (1C), (115.717+115.547) (1C), (113.064+112.906) (1C), 79.440 (1C), (59.604+59.441) (1C), (55.306+55.033) (1C), (47.134+46.587) (1C), 42.495 (1C), (35.003+34.778) (1C), 33.825 (1C), 28.579 (3C). MS (ESI, CH₃OH): [C₁₇H₂₇N₂O₂] *m/z* 311.2 ([M+H]⁺).

N¹-(3-fluorophenethyl)-N¹,N²-dimethylethane-1,2-diamine (60a)—To a mixture of **59a** (0.93 g, 0.003 mol) in anhydrous CH₂Cl₂ (4.5 mL) was added trifluoroacetic acid (TFA, 4.5 mL) at 0 °C. The reaction mixture was stirred for 1 h at 0 °C and 1 h at room temperature. After the reaction was finished, 2 M aqueous NaOH (30 mL) was added to adjust the pH value to basic. The mixture was stirred for an additional 10 min. The organic layer was separated. The aqueous layer was extracted with CH₂Cl₂ (30 mL × 2). The combined organic layers were washed with 2 M aqueous NaOH (30 mL × 2). The solvent was evaporated *in vacuo*. The residue was purified by column chromatography (silica gel, CH₂Cl₂: MeOH: Et₃N = 9.75: 0.25: 0.25) to afford a colorless oil (0.59 g, 93%). ¹H NMR (CDCl₃, 500 MHz): δ 7.255-7.212 (m, 1H), 6.971-6.956 (m, 1H), 6.907-6.866 (m, 2H), 2.757 (t, 2H, J=8Hz), 2.622-2.596 (m, 4H), 2.538 (t, 2H, J=5.5 Hz), 2.379 (s, 3H), 2.339 (brs, 1H), 2.330 (s, 3H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (163.943+161.994) (1C), (143.391+143.337) (1C), (129.858+129.791) (1C), (124.545+124.521) (1C), (115.735+115.572) (1C), (113.021+112.851) (1C), 59.277 (1C), 56.805 (1C), 49.344 (1C), 42.307 (1C), 36.423 (1C), 33.722 (1C). MS (ESI, CH₃OH): [C₁₂H₁₉FN₂] *m/z* 211.2 ([M+H]⁺).

(±)-tert-Butyl 3-{{6'-[benzyl(tert-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl} methyl}-4-hydroxypyrrolidine-1-carboxylate (61)—To an ice-cooled solution of sodium hydride (0.08 g, 0.002 mol, 60% dispersion in mineral oil) in anhydrous DMF (2 mL) was added dropwise **45a** (0.81 g, 0.002 mol) in anhydrous DMF (8 mL). The suspension was stirred vigorously for 30 min at 0 °C. The color of the reaction mixture changed from colorless to pale red. Benzyl bromide (0.34 g, 0.024 mL, 0.002 mol) was then added dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 30 min and was brought to room temperature over 1 h; stirring continued at room temperature for an additional hour. H₂O (5 mL) was added dropwise to quench the reaction. The reaction mixture was concentrated *in vacuo*, and the residue was diluted with H₂O (25 mL) and EtOAc (30 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (30 mL × 2). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes : EtOAc = 6 : 4) to afford a colorless oil (0.84g, 84%). ¹H NMR (CDCl₃, 500 MHz): δ 7.338-7.178 (m, 6H), 6.713-6.696 (m, 1H), 5.168-5.079 (m, 2H), (4.164+3.869) (brs, 1H), 4.061-4.042 (m, 1H), 3.726-3.528 (m, 2H), 3.211-3.144 (m, 1H), 3.094-3.044 (m, 1H), 2.812-2.765 (m, 2H), 2.488-2.364 (m, 1H), 2.296-2.289 (m, 3H), 1.452-1.416 (m, 18H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 157.398 (1C), (154.727+154.666) (1C), 154.405 (1C), 154.016 (1C), (149.463+149.341) (1C), (139.530+139.445) (1C), 128.340 (2C), 127.180 (1C), 126.871 (1C), (120.914+120.696) (1C), (118.577+118.358) (1C), 81.516 (1C), 79.416 (1C), (75.287+74.577) (1C), (52.798+52.367) (1C), (50.619+50.461) (1C), (49.817+49.404) (1C), (45.403+44.638) (1C), 39.368 (1C), 28.634 (3C), 28.294 (3C), 21.257 (1C). MS (ESI, CH₃OH): [C₂₈H₃₉N₃O₅] *m/z* 498.4 ([M+H]⁺); *m/z* 995.2 ([2M+H]⁺).

(±)-tert-Butyl 3-azido-4-{{6'-[benzyl(tert-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (62)—To Ph_3P (0.33 g, 0.00125 mol) in a dry THF (5 mL) solution was added **61** (0.5 g, 0.001 mol) in dry THF (10 mL) at 0 °C under a N_2 atmosphere *via* cannula. DIAD (0.26 g, 0.26 mL, 0.0013 mol) was added dropwise, and the solution was stirred at 0 °C for 20 min. DPPA (0.36 g, 0.28 mL, 0.0013 mol) was added dropwise at 0 °C, and the reaction mixture was stirred for 22 h at room temperature. The solvent was concentrated *in vacuo*. The crude residue was directly purified by column chromatography (silica gel, hexanes : EtOAc = 9 : 1) to afford a colorless oil (0.5 g, 95%). ^1H NMR (CDCl_3 , 500 MHz): δ 7.494-7.466 (m, 1H), 7.262-7.173 (m, 5H), 6.689 (m, 1H), 5.174 (m, 2H), 3.779-3.735 (m, 1H), 3.579-3.468 (m, 1H), 3.443-3.367 (m, 1H), 3.322-3.280 (m, 1H), 3.030-2.966 (m, 1H), 2.879-2.834 (m, 1H)-2.745-2.692 (m, 1H), 2.669-2.590 (m, 1H), 2.302-2.289 (m, 3H), 1.462-1.443 (m, 9H), 1.417 (s, 9H). ^{13}C NMR (CDCl_3 , 125.7 MHz): δ (156.603+156.585) (1C), (154.338+154.302+154.089) (2C), 153.943 (1C), 148.710 (1C), (139.827+139.754) (1C), (128.115+128.085) (2C), (126.743+126.634) (2C), (126.555+126.458) (1C), 119.931 (1C), (117.089+117.041) (1C), (81.249+81.201) (1C), 79.489 (1C), (63.229+62.470) (1C), (51.487+51.201) (1C), 49.908 (1C), (48.846+48.445) (1C), (42.513+41.942) (1C), (34.972+34.912) (1C), 28.452 (3C), 28.130 (3C), 21.117 (1C). MS (ESI, CH_3OH): $[\text{C}_{28}\text{H}_{38}\text{N}_6\text{O}_4]$ m/z 523.2 ($[\text{M}+\text{H}]^+$); m/z 1066.9 ($[\text{2M}+\text{Na}]^+$).

(±)-tert-Butyl 3-amino-4-{{6'-(tert-butoxycarbonylamino)-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (63)—A solution of **62** (0.52 g, 0.001 mol) in EtOH (20 mL) was treated with 20% wt $\text{Pd}(\text{OH})_2$ on carbon (300 mg). The reaction mixture was stirred at 60 °C under a hydrogen atmosphere for 36 h. The catalyst was filtered through Celite. The Celite pad was washed with EtOH (10 mL \times 2). The combined filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, CH_2Cl_2 : CH_3OH = 9.5 : 0.5) to afford a pale-green oil (0.28 g, 69%). ^1H NMR (CDCl_3 , 500 MHz): δ 7.690 (brs, 1H), 7.635-7.626 (m, 1H), 6.645 (m, 1H), 3.563-3.173 (m, 4H), 2.832-2.772 (m, 1H), 2.720-2.659 (m, 2H), 2.478 (m, 1H), 2.307-2.296 (m, 3H), 1.518 (s, 9H), 1.454-1.446 (m, 9H). ^{13}C NMR (CDCl_3 , 125.7 MHz): δ 157.860 (1C), (154.745+154.678) (1C), 152.602 (1C), 151.600 (1C), 150.270 (1C), 118.868 (1C), 110.447 (1C), (80.836+80.782) (1C), 79.294 (1C), (54.274+53.891) (1C), (52.513+51.365) (1C), (48.815+48.396) (1C), (43.904+43.199) (1C), (35.264+35.082) (1C), 28.561 (3C), 28.336 (3C), 21.378 (1C). MS (ESI, CH_3OH): $[\text{C}_{21}\text{H}_{34}\text{N}_4\text{O}_4]$ m/z 407.4 ($[\text{M}+\text{H}]^+$); m/z 429.2 ($[\text{M}+\text{Na}]^+$).

(±)-tert-Butyl 3-{2'-[tert-butoxycarbonyl(4''-chlorobenzyl)amino]ethylamino}-4-{{6'-(tert-butoxycarbonylamino)-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (47b) or (±)-tert-Butyl 3-{2'-[tert-butoxycarbonyl(3''-fluorophenethyl)amino]ethylamino}-4-{{6'-(tert-butoxycarbonylamino)-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (47m)—To a mixture of **63** (0.203 g, 0.5 mmol), $\text{NaBH}(\text{OAc})_3$ (0.127 g, 0.6 mmol), and 3 Å molecular sieves (0.5 g) in dry 1,2-dichloroethane (10 mL) were added **56a** (0.142 g, 0.5 mmol) or **56b** (0.141 g, 0.5 mmol) in dry 1,2-dichloroethane (5 mL) *via* cannula under a N_2 atmosphere. The reaction mixture was stirred at room temperature under a N_2 atmosphere for 16 h and then was filtered through Celite, and the Celite pad was washed with CH_2Cl_2 (5 mL \times 2). To the filtrate was then added 1 M aqueous NaOH (10 mL). The organic layer was separated, and the aqueous layer was extracted with CH_2Cl_2 (10 mL \times 2). The combined organic layers were washed with brine (10 mL) and dried over MgSO_4 . The solvent was evaporated, and the residue was purified by column chromatography (silica gel, hexanes : EtOAc : Et_3N = 8 : 2 : 0.25) to afford a colorless oil (**47b**, 0.306 g, 91%). ^1H NMR (CDCl_3 , 500 MHz): δ 7.625-7.608 (m, 1H), 7.478 (brs, 1H), 7.281 (s, 2H), 7.187 (s, 2H), 6.642 (s, 1H), 4.569-4.339 (m, 2H), 3.339-3.110 (m, 7H), 2.764-2.567 (m, 5H), 2.300-2.286 (m, 3H), 1.508-1.452 (m, 27H). ^{13}C NMR (CDCl_3 , 125.7 MHz): δ 158.210 (1C), 155.818 (1C), (154.792+154.695) (1C), (152.539+152.503) (1C),

151.453 (1C), 149.819 (1C), 137.191 (1C), 132.892 (1C), (129.073+128.655+128.618+128.412) (4C), 119.159 (1C), 110.264 (1C), 80.691 (1C), (80.108+79.986) (1C), 79.106 (1C), (59.295+58.245) (1C), (50.686+50.182) (2C), (49.326+49.022) (1C), (47.310+46.873) (1C), (46.236+46.114) (1C), (42.538+41.646) (1C), (35.034+34.882) (1C), 28.519 (3C), 28.422 (3C), 28.264 (3C), 21.288 (1C). MS (ESI, CH₃OH): [C₃₅H₅₂ClN₅O₆] *m/z* 674.3 ([M+H]⁺). Or a colorless oil (**47m**, 0.295 g, 88%). ¹H NMR (CDCl₃, 500 MHz): δ 7.611-7.596 (m, 1H), 7.376 (brs, 1H), 7.266-7.223 (m, 1H), 6.945-6.902 (m, 3H), 6.636 (s, 1H), 3.424-3.115 (m, 9H), 2.819-2.785 (m, 4H), 2.619-2.523 (m, 3H), 2.295-2.280 (m, 3H), 1.511-1.441 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ, (163.907+161.952) (1C), 158.272 (1C), 155.656 (1C), (154.866+154.769) (1C), (152.589+152.547) (1C), 151.466 (1C), (149.900+149.869) (1C), (141.825+141.770) (1C), 129.961 (1C), (124.636+124.618) (1C), (119.239+119.202) (1C), (115.857+115.693) (1C), (113.337+113.167) (1C), (110.295+110.235) (1C), (80.788+80.727) (1C), 79.744 (1C), 79.161 (1C), (59.465+58.384) (1C), (50.801+50.303) (1C), (49.372+49.064) (2C), 47.486 (1C), (46.879+46.551+46.253) (1C), (42.483+41.621) (1C), (35.088+34.918+34.329) (2C), 28.567 (3C), 28.464 (3C), 28.318 (3C), 21.342 (1C). ¹⁹F NMR (CDCl₃, 376.5 MHz): δ -113.945 (Ar-F). MS (ESI, CH₃OH): [C₃₆H₅₄FN₅O₆] *m/z* 672.4 ([M+H]⁺).

(±)-tert-Butyl 3-azido-4-([2'-(tert-butoxycarbonylamino)-6'-methylpyridin-4'-yl]methyl)pyrrolidine-1-carboxylate (64)—To Ph₃P (0.984 g, 0.00375 mol) in dry THF (5 mL) solution was added **45b** (1.222 g, 0.003 mol) in THF (10 mL) at 0 °C under a nitrogen atmosphere via a cannula. DIAD (0.789 g, 0.778 mL, 0.0039 mol) was then added dropwise, and the solution was stirred for 20 min at 0 °C. After addition of DIAD, DPPA (1.032 g, 0.808 mL, 0.00375 mol) was added at 0 °C, and the solution was stirred overnight at room temperature. The solution was concentrated, and the crude residue was purified by column chromatography (silica gel, hexanes: EtOAc = 8 : 2) to afford a colorless oil (0.674 g, 52%). ¹H NMR (CDCl₃, 500MHz): δ (8.325+8.275) (s, 1H), (7.666+7.654) (s, 2H), (6.688+6.670) (s, 1H), 3.977-3.945 (m, 1H), (3.724+3.699+3.633+3.609) (m, 1H), 3.528-3.438 (m, 2H), 3.103-3.050 (m, 1H), 2.839-2.791 (m, 1H), 2.712-2.653 (m, 1H), 2.579-2.522 (m, 1H), (2.430+2.411) (s, 3H), 1.493 (s, 9H), 1.460 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (157.059+157.029) (1C), (154.275+154.092) (1C), (152.738+152.709) (1C), (152.047+151.983) (1C), 151.066 (1C), 118.485 (1C), 109.140 (1C), (80.676+80.634) (1C), 79.785 (1C), (63.102+62.206) (1C), (51.452+51.125) (1C), (48.762+48.405) (1C), (44.373+43.737) (1C), (33.390+33.288) (1C), 28.450 (3C), 28.259 (3C), 23.824 (1C).

(±)-tert-Butyl 3-amino-4-([6'-(tert-butoxycarbonylamino)-4'-methylpyridin-2'-yl]methyl)pyrrolidine-1-carboxylate (65)—To an ice-cooled solution of **64** (0.649 g, 0.0015 mol) in THF (5 mL) was added Ph₃P (0.472 g, 0.0018 mol) and water (0.081 g, 0.081 mL, 0.0045 mol). The reaction mixture was stirred for 2 h at 0 °C and for 21 h at room temperature. The solvent was removed in vacuo, and the residue was purified by column chromatography (silica gel, CH₂Cl₂ : MeOH = 9 : 1) to afford a pale-green oil (0.537 g, 88%). ¹H NMR (CDCl₃, 500MHz): δ (8.494+8.430) (s, 1H), (7.548+7.537) (s, 2H), (6.563+6.549) (s, 1H), 3.379-3.243 (m, 3H), 3.178-3.105 (m, 1H), 3.071-3.014 (m, 1H), 2.717-2.679 (m, 1H), 2.522-2.466 (m, 1H), 2.400-2.305 (m, 1H), (2.305+2.285) (s, 3H), 1.371 (s, 9H), 1.329 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 156.706 (1C), (154.593+154.551) (1C), 152.696 (1C), (151.991+151.924) (1C), (151.817+151.745) (1C), 118.239 (1C), (109.217+109.166) (1C), (80.426+80.400) (1C), (79.136+79.114) (1C), (54.932+54.427) (1C), (52.666+51.652) (1C), (48.329+47.930) (1C), (44.047+43.435) (1C), (33.114+32.919) (1C), 28.395 (3C), 28.170 (3C), 23.727 (1C). MS (ESI, CH₃OH): [C₂₁H₃₄N₄O₄] *m/z* 407.3([M+H]⁺); *m/z* 813.1([2M+H]⁺); *m/z* 835.2([2M+Na]⁺).

(±)-tert-Butyl 3-{2-[tert-butoxycarbonyl(4-chlorobenzyl)amino]ethylamino}-4-[[2-(tert-butoxycarbonylamino)-6-methylpyridin-4-yl]methyl]pyrrolidine-1-carboxylate (66a)—To a mixture of **65** (0.203 g, 0.5 mmol), NaBH(OAc)₃ (0.127 g, 0.6 mmol), and 3 Å molecular sieves (0.5 g) in dry 1,2-dichloroethane (10 mL) was added **56a** (0.142 g, 0.5 mmol) in dry 1,2-dichloroethane (5 mL) *via* cannula under a N₂ atmosphere. The reaction mixture was stirred at room temperature under a N₂ atmosphere for 16 h and then was filtered through Celite, and the Celite pad was washed with CH₂Cl₂ (5 mL × 2). To the filtrate was then added 1 M aqueous NaOH (10 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (10 mL × 2). The combined organic layers were washed with brine (10 mL) and dried over MgSO₄. The solvent was evaporated, and the residue was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9 : 1 : 0.25) to afford a colorless oil (0.283 g, 84%). ¹H NMR (CDCl₃, 500 MHz): δ (8.209+8.152) (s, 1H), (7.641+7.636) (s, 1H), 7.301-7.285 (m, 2H), 7.199 (m, 2H), 6.642 (s, 1H), 4.454 (s, 2H), 3.370-3.092 (m, 7H), 2.796 (m, 2H), 2.660 (m, 1H), 2.446 (m, 2H), (2.413+2.391) (s, 3H), 1.523-1.417 (m, 27H). ¹³C NMR (CDCl₃, 100.7 MHz): δ 156.659 (1C), 155.901 (1C), (154.780+154.727) (1C), 152.629 (1C), 152.235 (1C), (151.857+151.781) (1C), (137.209+137.057) (1C), 132.914 (1C), (129.074+128.658+128.430) (4C), 118.645 (1C), (109.374+109.298) (1C), 80.517 (1C), 80.070 (1C), 79.298 (1C), (59.264+58.401) (1C), 50.819 (1C), 50.183 (1C), (48.858+48.646) (1C), (47.222+47.063) (1C), 46.358 (1C), (43.139+42.473) (1C), (32.854+32.664) (1C), 28.491 (6C), 28.249 (3C), 23.826 (1C). MS (ESI, CH₃OH): [C₃₅H₅₂ClN₅O₆] *m/z* 674.5 ([M+H]⁺).

N¹-{(±)-4'-[(2"-amino-6"-methylpyridin-4"-yl)methyl]pyrrolidin-3'-yl}-N²-(4'-chlorobenzyl)ethane-1,2-diamine tetrahydrochloride (27)—The procedure to prepare **27** is the same as that to prepare **7** except using **66a** (0.135 g, 0.2 mmol) instead of **37a**, affording a hygroscopic white solid (0.104 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.4455 (d, 2H, J = 8.5 Hz), 7.3765 (d, 2H, J = 8.5 Hz), 6.700 (s, 1H), 6.632 (s, 1H), 4.374-4.334 (m, 1H), 4.317 (s, 2H), 3.990-3.948 (m, 1H), 3.781-3.741 (m, 1H), 3.678-3.604 (m, 4H), 3.443-3.405 (m, 1H), 3.305-3.266 (m, 1H), 3.161-3.140 (m, 2H), 2.720-2.665 (m, 1H), 2.355 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ 155.550 (1C), 153.724 (1C), 147.332 (1C), 135.357 (1C), 131.639 (2C), 129.389 (2C), 128.768 (1C), 113.279 (1C), 109.818 (1C), 58.746 (1C), 51.089 (1C), 47.454 (1C), 45.219 (1C), 43.523 (1C), 42.977 (1C), 39.622 (1C), 31.624 (1C), 18.453 (1C). MS (ESI, CH₃OH): [C₂₀H₂₈ClN₅] *m/z* 374.81 ([M+H]⁺). HRMS (ESI, CH₃OH) Calc.: 374.2111, Found: 374.2106.

N¹-{(±)-4'-[(2"-amino-6"-methylpyridin-4"-yl)methyl]pyrrolidin-3'-yl}-N²-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride (28)—The procedure to prepare **28** is the same as that to prepare **7** except using **66b** (0.134 g, 0.2 mmol) instead of **37a**, affording a hygroscopic white solid (0.103 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.316-7.306 (m, 1H), 7.086-7.076 (m, 1H), 7.029-6.971 (m, 2H), 6.708 (s, 1H), 6.632 (s, 1H), 4.351 (m, 1H), 3.972-3.960 (m, 1H), 3.776-3.751 (m, 1H), 3.610 (m, 4H), 3.407 (m, 3H), 3.292-3.272 (m, 1H), 3.161-3.142 (m, 2H), 3.030 (m, 2H), 2.721-2.670 (m, 1H), 2.357 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ (163.889+161.473) (1C), 155.557 (1C), 153.717 (1C), 147.309 (1C), (138.485+138.410) (1C), (130.889+130.805) (1C), (124.966+124.943) (1C), (115.832+115.620) (1C), (114.377+114.173) (1C), 113.279 (1C), 109.795 (1C), 58.746 (1C), 49.226 (1C), 47.446 (1C), 45.234 (1C), 43.523 (2C), 39.622 (1C), 31.601 (2C), 18.445 (1C). ¹⁹F NMR (D₂O, 376.5 MHz): δ -113.609 (Ar-F). MS (ESI, CH₃OH): [C₂₁H₃₀FN₅] *m/z* 372.6 ([M+H]⁺). HRMS (ESI, CH₃OH) Calc.: 372.2563, Found: 372.2556.

Enzyme and assay

All of the NOS isozymes used were recombinant enzymes overexpressed in *E.coli*. The murine macrophage iNOS was expressed and isolated according to the procedure of Hevel et al.⁵⁰

The rat nNOS was expressed⁵¹ and purified as described.⁵² The bovine eNOS was isolated as reported.⁵³ Nitric oxide formation from NOS was monitored by the hemoglobin capture assay as described at 30 °C.⁵⁴ A typical assay mixture for nNOS and eNOS contained 10 μ M L-arginine, 1.0 mM CaCl₂, 600 unit/mL calmodulin (Sigma, P-2277), 100 μ M NADPH, 0.125 mg/mL hemoglobin-A₀ (ferrous form, Sigma, H0267), 10 μ M H₄B, in 100 mM HEPES (pH 7.5). A typical assay mixture for iNOS contained 10 μ M L-arginine, 100 μ M NADPH, 0.125 mg/mL hemoglobin-A₀ (ferrous form), 10 μ M H₄B, in 100 mM HEPES (pH 7.5). All assays were in a final volume of 600 μ L and were initiated by addition of enzyme. NOS assays were monitored at 401 nm on a Perkin-Elmer Lambda 10 UV-visible spectrophotometer.

Determination of K_i values

The apparent K_i values were obtained by measuring the percent enzyme inhibition in the presence of 10 μ M L-arginine with at least five concentrations of inhibitor. The parameters of the following inhibition equation⁵⁵ were fitted to the initial velocity data: % inhibition = $100 [I] / \{ [I] + K_i (1 + [S]/K_m) \}$. K_m values for L-arginine were 1.3 μ M (nNOS), 8.2 μ M (iNOS), and 1.7 μ M (eNOS). The selectivity of an inhibitor was defined as the ratio of the respective K_i values.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors are grateful for financial support from the National Institutes of Health, GM 49725 to RBS, GM57353 to TLP, and GM52419 to Dr. Bettie Sue Masters, with whose lab PM and LJR are affiliated, and Grant No. AQ1192 from The Robert A. Welch Foundation to BSM. P.M. is also supported by Grant KAN200200651 from Academy of Science, Czech Republic.

Abbreviations

NO, nitric oxide
 NOS, nitric oxide synthase
 nNOS, neuronal NOS
 iNOS, inducible NOS
 eNOS, endothelial NOS
 SAR, structure-activity relationship
 HTS, high throughput screening
 sGC, soluble guanylate cyclase
 GTP, guanosine 5'-triphosphate
 cGMP, guanosine 3',5'-cyclic monophosphate
 NADPH, reduced nicotinamide adenine dinucleotide phosphate
 FAD, flavin adenine dinucleotide
 FMN, flavin mononucleotide
 H₄B, (6*R*)-5,6,7,8-tetrahydro-L-biopterin
 CaM, calmodulin
 CPCA, consensus principle component analysis
 MCSS, multiple copy simultaneous search
 BBB, blood brain barrier
 MIFs, molecular interaction fields
 PSA, polar surface area
 RMSD, root-mean-square deviation
 DIAD, diisopropyl azodicarboxylate

DPPA, diphenylphosphoryl azide

References

1. (a) Erlanson DA, McDowell RS, O'Brien T. Fragment-based drug discovery. *J. Med. Chem* 2004;47(14):3463–3482. [PubMed: 15214773] (b) Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. *Nat. Rev. Drug Discov* 2004;3(8):660–672. [PubMed: 15286733] (c) Erlanson DA. Fragment-based lead discovery: a chemical update. *Curr. Opin. Biotechnol* 2006;17(6):643–652. [PubMed: 17084612] (d) Congreve M, Chessari G, Tisi D, Woodhead AJ. Recent developments in fragment-based drug discovery. *J. Med. Chem* 2008;51(13):3661–3680. [PubMed: 18457385]
2. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. *Nat. Rev. Drug Discov* 2007;6(3):211–219. [PubMed: 17290284]
3. (a) Mauser H, Guba W. Recent developments in de novo design and scaffold hopping. *Curr. Opin. Drug Discov. Devel* 2008;11(3):365–374. (b) Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. *Nat. Rev. Drug Discov* 2005;4(8):649–663. [PubMed: 16056391]
4. Ji H, Stanton BZ, Igarashi J, Li H, Martásek P, Roman LJ, Poulos TL, Silverman RB. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. *J. Am. Chem. Soc* 2008;130(12):3900–3914. [PubMed: 18321097]
5. (a) Bredt DS, Snyder SH. Nitric oxide: A Physiologic Messenger Molecule. *Annu. Rev. Biochem* 1994;63:175–195. [PubMed: 7526779] (b) Kerwin JF Jr, Lancaster JR Jr, Feldman PL. Nitric oxide: A New Paradigm for Second Messengers. *J. Med. Chem* 1995;38(22):4343–4362. [PubMed: 7473563]
6. Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA. The Chemical Biology of Nitric Oxide: Implications in Cellular Signaling. *Free Radic. Biol. Med* 2008;45(1):18–31. [PubMed: 18439435]
7. Cary SPL, Winger JA, Derbyshire ER, Marletta MA. Nitric Oxide Signaling: No Longer Simply On or Off. *Trends Biochem. Sci* 2006;31(4):231–239. [PubMed: 16530415]
8. Moncada S, Palmer RM, Higgs EA. Nitric Oxide: Physiology, Pathophysiology, and Pharmacology. *Pharmacol. Rev* 1991;43(2):109–142. [PubMed: 1852778]
9. Domenico R. Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies. *Curr. Pharm. Des* 2004;10(14):1667–1676. [PubMed: 15134564]
10. Rosen GM, Tsai P, Pou S. Mechanism of Free-Radical Generation by Nitric Oxide Synthase. *Chem. Rev* 2002;102(4):1191–1199. [PubMed: 11942793]
11. Knowles RG, Moncada S. Nitric Oxide Synthases in Mammals. *Biochem. J* 1994;298(2):249–258. [PubMed: 7510950]
12. Alderton WK, Cooper CE, Knowles RG. Nitric Oxide Synthases: Structure, Function and Inhibition. *Biochem. J* 2001;357(3):593–615. [PubMed: 11463332]
13. Roman LJ, Martásek P, Masters BSS. Intrinsic and Extrinsic Modulation of Nitric Oxide Synthase Activity. *Chem. Rev* 2002;102(4):1179–1189. [PubMed: 11942792]
14. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of Cerebral Ischemia in Mice Deficient in Neuronal Nitric Oxide Synthase. *Science* 1994;265(5180):1883–1885. [PubMed: 7522345]
15. (a) Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of Neuronal Nitric Oxide in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Dopaminergic Neurotoxicity. *Proc. Natl. Acad. Sci. U. S. A* 1996;93(10):4565–4571. [PubMed: 8643444] (b) Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF. Inhibition of Neuronal Nitric Oxide Synthase prevents MPTP-induced Parkinsonism in Baboons. *Nat. Med* 1996;2(9):1017–1021. [PubMed: 8782460]
16. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, Lipton SA. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. *Nature* 2006;441(7092):513–517. [PubMed: 16724068]
17. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. *Science* 2005;310(5756):1966–1970. [PubMed: 16373578]

18. (a) Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in Mice Lacking the Gene for Endothelial Nitric Oxide Synthase. *Nature* 1995;377(6546):239–242. [PubMed: 7545787] (b) Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for Stroke Protection. *Trends Neurosci* 2004;27(5):283–289. [PubMed: 15111011] (c) Braam B, Verhaar MC. Understanding eNOS for Pharmacological Modulation of Endothelial Function: A Translational View. *Curr. Pharm. Des* 2007;13(17):1727–1740. [PubMed: 17584103]
19. (a) Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. *Curr. Pharm. Des* 2002;8(3):177–200. [PubMed: 11812267] (b) Erdal EP, Litzinger EA, Seo J, Zhu Y, Ji H, Silverman RB. Selective neuronal nitric oxide synthase inhibitors. *Curr. Top. Med. Chem* 2005;5(7):603–624. [PubMed: 16101423] (c) Tafi A, Angeli L, Venturini G, Travagli M, Corelli F, Botta M. Computational studies of competitive inhibitors of nitric oxide synthase (NOS) enzymes: towards the development of powerful and isoform-selective inhibitors. *Curr. Med. Chem* 2006;13(16):1929–1946. [PubMed: 16842203]
20. Vallance P, Leiper J. Blocking NO Synthesis: How, Where and Why? *Nat. Rev. Drug Discov* 2002;1(12):939–950. [PubMed: 12461516]
21. (a) Silverman RB, Huang H, Marletta MA, Martásek P. Selective Inhibition of Neuronal Nitric Oxide Synthase by N^ω-Nitroarginine-and Phenylalanine-Containing Dipeptides and Dipeptide esters. *J. Med. Chem* 1997;40(18):2813–2817. [PubMed: 9288162] (b) Zhang HQ, Fast W, Marletta MA, Martásek P, Silverman RB. Potent and Selective Inhibition of Neuronal Nitric Oxide Synthase by N^ω-propyl-L-arginine. *J. Med. Chem* 1997;40(24):3869–3870. [PubMed: 9397167]
22. (a) Crane BR, Arvai AS, Ghosh DK, Wu C, Getzoff ED, Stuehr DJ, Tainer JA. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. *Science* 1998;279(5359):2121–2126. [PubMed: 9516116] (b) Raman CS, Li H, Martásek P, Kral V, Masters BS, Poulos TL. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. *Cell* 1998;95(7):939–950. [PubMed: 9875848] (c) Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. *Nat. Struct. Biol* 1999;6(3):233–242. [PubMed: 10074942] (d) Li H, Shimizu H, Flinspach M, Jamal J, Yang W, Xian M, Cai T, Wen EZ, Jia Q, Wang PG, Poulos TL. The novel binding mode of *N*-alkyl-*N'*-hydroxyguanidine to neuronal nitric oxide synthase provides mechanistic insights into NO biosynthesis. *Biochemistry* 2002;41(47):13868–13875. [PubMed: 12437343]
23. Ji H, Tan S, Igarashi J, Li H, Derrick M, Martásek P, Roman LJ, Vásquez-Vivar J, Poulos TL, Silverman RB. Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. *Ann. Neurol.* 2008in press
24. Huang H, Martásek P, Roman LJ, Masters BS, Silverman RB. N^ω-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase. *J. Med. Chem* 1999;42(16):3147–3153. [PubMed: 10447959]
25. Gómez-Vidal JA, Martásek P, Roman LJ, Silverman RB. Potent and selective conformationally restricted neuronal nitric oxide synthase inhibitors. *J. Med. Chem* 2004;47(3):703–710. [PubMed: 14736250]
26. Ji H, Gómez-Vidal JA, Martásek P, Roman LJ, Silverman RB. Conformationally restricted dipeptide amide as potent and selective neuronal nitric oxide synthase inhibitors. *J. Med. Chem* 2006;49(21):6254–6263. [PubMed: 17034131]
27. Hah J-M, Roman LJ, Martásek P, Silverman RB. Reduced amide bond peptidomimetics. (4*S*)-*N*-(4-amino-5-[aminoalkyl]aminopentyl)-*N'*-nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. *J. Med. Chem* 2001;44(16):2667–2670. [PubMed: 11472219]
28. Hah J-M, Martásek P, Roman LJ, Silverman RB. Aromatic reduced amide bondpeptidomimetics as selective inhibitors of neuronal nitric oxide synthase. *J. Med. Chem* 2003;46(9):1661–1669. [PubMed: 12699384]
29. (a) Flinspach ML, Li H, Jamal J, Yang W, Huang H, Hah J-M, Gómez-Vidal JA, Litzinger EA, Silverman RB, Poulos TL. Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase. *Nat. Struct. Mol. Biol* 2004;11(1):54–59. [PubMed: 14718923] (b) Flinspach M, Li H, Jamal J, Yang W, Huang H, Silverman RB, Poulos TL. Structures of the Neuronal and Endothelial Nitric Oxide Synthase Heme Domain with D-Nitroarginine-Containing Dipeptide

Inhibitors Bound. *Biochemistry* 2004;43(18):5181–5187. [PubMed: 15122883] Li H, Flinspach ML, Igarashi J, Jamal J, Yang W, Gómez-Vidal JA, Litzinger EA, Huang H, Erdal EP, Silverman RB, Poulos TL. Exploring the binding conformations of bulkier dipeptide amide inhibitors in constitutive nitric oxide synthases. *Biochemistry* 2005;44(46):15222–15229. [PubMed: 16285725]

30. Ji H, Li H, Flinspach M, Poulos TL, Silverman RB. Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. *J. Med. Chem* 2003;46(26):5700–5711. [PubMed: 14667223]
31. (a) Wade RC, Goodford PJ. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand and probe groups with the ability to form two hydrogen bonds. *J. Med. Chem* 1993;36(1):140–147. [PubMed: 8421280] (b) Wade RC, Goodford PJ. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand and probe groups with the ability to form more than two hydrogen bonds. *J. Med. Chem* 1993;36(1):148–156. [PubMed: 8421281]
32. Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. *Proteins* 1991;11(1):29–34. [PubMed: 1961699]
33. (a) Böhm H-J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. *J. Comput.-Aided Mol. Des* 1992;6(1):61–78. [PubMed: 1583540] (b) Böhm H-J. LUDI: Rule-Based Automatic Design of New Substituents for Enzyme Inhibitor Leads. *J. Comput.-Aided Mol. Des* 1992;6(6):593–606. [PubMed: 1291628]
34. Lawton GR, Ji H, Silverman RB. Remote protection prevents unwanted cyclizations with 2-aminopyridines. *Tetrahedron Lett* 2006;47(34):6113–6115.
35. Igarashi J, Li H, Jamal J, Ji H, Fang J, Silverman RB, Poulos TL. Crystal structures of constitutive nitric oxide synthases in complex with de novo designed inhibitors. *J. Biol. Chem.* 2008submitted
36. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. *J. Med. Chem* 2000;43(20):3714–3717. [PubMed: 11020286]
37. BioByte Corp.. 201 W. Fourth Street, Suite 204, Claremont, CA 91711. (<http://www.biobyte.com/>)
38. ACD/log D suite, Advanced Chemistry Development Inc.. 110 Yonge Street, 14th floor, Toronto-Ontario, Canada M5C 1T4. (<http://www.acdlabs.com>)
39. Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, Howe T, Vianello R. MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist. *J. Med. Chem* 2005;48(22):6970–6979. [PubMed: 16250655]
40. Garcin ED, Arvai AS, Rosenfeld RJ, Kroeger MD, Crane BR, Andersson G, Andrews G, Hamley PJ, Mallinder PR, Nicholls DJ, St-Gallay SA, Tinker AC, Gensmantel NP, Mete A, Cheshire DR, Connolly S, Stuehr DJ, Aberg A, Wallace AV, Tainer JA, Getzoff ED. Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. *Nature Chem. Biol* 2008;4(11):700–707. [PubMed: 18849972]
41. Silverman RB. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors for the Prevention and Treatment of Neurodegenerative Diseases. *Acc. Chem. Res.* In press
42. Insight II 2000: Accelrys Inc.. 10188 Telesis Court, Suite 100, San Diego, CA 92121, Phone: (858) 799-5000 Fax: (858) 799-5100. <http://www.accelrys.com/>
43. SYBYL 6.8: Tripos, Inc.. 1699 South Hanley Road St. Louis, MO 63144-2319 Phone: (800) 323-2960. Fax: (314) 647-9241. <http://www.tripos.com/>
44. GRID 22: Molecular Discovery, Via Stoppani, 38, 06087 - Ponte San Giovanni - PG, ITALY. Telephone and fax: +39-075-397411. (<http://www.moldiscovery.com/>)
45. Evensen, ER.; Joseph-McCarthy, D.; Karplus, M. MCSS, version 2.1. Harvard University; Cambridge, MA: 1997.
46. Böhm H-J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. *J. Comput.-Aided Mol. Des* 1994;8(3):243–256. [PubMed: 7964925]
47. Morris GM, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J. Comp. Chem* 1998;19(14):1639–1662.

48. Weiner SJ, Kollman PA, Case DA, Singh UC, Ghio C, Alagona G, Profeta S, Weiner P. A new force field for molecular mechanical simulation of nucleic acid and proteins. *J. Am. Chem. Soc* 1984;106(3):765–784.
49. Gasteiger J, Marsili M. Iterative paratotal equalization of orbital electronegativity - a rapid access to atomic charges. *Tetrahedron* 1980;36(22):3219–3228.
50. Hevel JM, White KA, Marletta M. A purification of the inducible murine macrophage nitric oxide synthase. *J. Biol. Chem* 1991;266(34):22789–22791. [PubMed: 1720773]
51. Roman LJ, Sheta EA, Martásek P, Gross SS, Liu Q, Masters BSS. High-level expression of functional rat neuronal nitric oxide synthase in *Escherichia coli*. *Proc.Natl. Acad. Sci. U.S.A* 1995;92(18):8428–8432. [PubMed: 7545302]
52. Gerber NC, Ortiz de Montellano PR. Neuronal nitric oxide synthase: expression in *Escherichia coli*, irreversible inhibition by phenyldiazene, and active site topology. *J. Biol. Chem* 1995;270(30):17791–17796. [PubMed: 7543092]
53. Martasek P, Liu Q, Roman LJ, Gross SS, Sessa WC, Masters BSS. Characterization of bovine endothelial nitric oxide synthase expressed in *Escherichia coli*. *Biochem. Biophys. Res. Commun* 1996;219(2):359–365. [PubMed: 8604992]
54. Hevel JM, Marletta MA. Nitric oxide synthase assays. *Methods Enzymol* 1994;233:250–258. [PubMed: 7516999]
55. Segel, IH. *Enzyme Kinetics*. John Wiley and Sons; NewYork: 1975. p. 105





Figure 1.

Schematic drawing of the active site of nNOS. The binding mode of **6** and the amino acids and cofactors important for inhibitor binding are indicated. Numbering is for the sequence of rat nNOS. The H-bonds observed in the crystal structure are indicated by dotted lines (PDB id: 3B3N). Under physiological conditions, the nitrogen atoms of the pyridine ring, the pyrrolidine ring, and the terminal amino group of the ethylenediamine side chain of **6** in NOS are protonated, but the nitrogen atom attached to the pyrrolidine ring is unaffected.







Figure 2.

Results of GRID analysis of the substrate binding site of nNOS (PDB id: 1P6I). The residues and inhibitor **6** are represented in an atom-type style. Heme and H₄B are colored magenta. The S, M, and C1 pockets are indicated. A: GRID contours of the DRY probe at an energy level of -0.75 kcal/mol. B: GRID contours of the C3⁺ probe at an energy level of -2.75 kcal/mol; “x” represents the position of the heme iron atom.








Figure 3.


Representative MCSS-minimized positions of the functional groups in the active site of rat nNOS (PDB id: 1P6I). Cofactors heme and H₄B are shown in gray and magenta, respectively. Inhibitor **6** is shown in the ball-and-stick model (an atom-type style). The S, M, and C1 pockets are indicated. A: Benzene (red, minimum No. 1 in the S pocket, minimum No. 7 in the C1 pocket, and minimum No. 8 in the M pocket); cyclohexane (yellow, minimum No. 1 in the S pocket, minimum No. 3 in the M pocket, and minimum No. 6 in the C1 pocket). B: isobutane (red, minimum No. 1 in the S pocket, minimum No. 3 in the M pocket, and No. 13 in the C1 pocket); *n*-butane (yellow, minimum No. 1 in the S pocket, minimum No. 12 in the M pocket, and minimum No. 52 in the C1 pocket); and propane (cyan, minimum No. 1 in the S pocket, minimum No. 6 in the M pocket and minimum No. 14 in the C1 pocket).



A



B



C

Figure 4.
Molecules designed and synthesized.




Figure 5.

The predicted binding conformation of **7** in the active site of nNOS. Cofactors heme and H₄B are shown in gray and purple, respectively. Inhibitor **7** is shown in an atom-type style. The potential H-bonds are indicated by dotted lines.






Figure 6.

A. The docking conformation of **24** in the active site of rat nNOS. Inhibitor **24** is shown in an atom-type style. B. The superimposition of the docking conformation of **25** and **26** in the active site of rat nNOS. Inhibitor **25** is colored yellow and **26** colored blue. Cofactors heme and H₄B are shown in gray and purple, respectively. The potential H-bonds are indicated by dotted lines.


A.



B.




Scheme 1.




Scheme 2.


A.




B.




C.



Scheme 3.



Scheme 4.



Scheme 5.

Table 1
The inhibitory activities of **1-6** toward three isozymes of nitric oxide synthase (NOS)

No.	K_i (μ M)			Selectivity ^a		
	nNOS	eNOS	iNOS	n/e	n/i	
1	0.13	200	25	1538	192	
2	0.10	128	29	1280	290	
3	0.087	200	5.76	2299	66	
4	0.10	314	39	2617	325	
5	0.05	105	3.51	2121	70.2	
(±)-6	0.388	434.5	58.4	1114	150	

^a n/e and n/i are the selectivity ratios of inhibition of nNOS/eNOS and nNOS/iNOS, respectively (inhibition of nNOS is greater than eNOS and iNOS in all examples).




Table 2

Summary of the main probe interactions observed in the active site of rat nNOS. The relevant residues and cofactors and the maximal interaction energy involved in a particular interaction are given. Heme propionate A and D means the heme propionate of the pyrrole A ring and D ring, respectively

Probe	Chemical group	Pocket	Maximal energy (kcal/mol)	Main residues and cofactors
DRY	hydrophobic probe	C1	-1.85	Y706, L337, M336, W306 (the other NOS monomer)
		S	-0.80	P565, A566, V567, F584, S585, G586, heme
C3	methyl group	S	-5.00	P565, A566, V567, F584, S585, G586, heme
		M	-4.00	D597, heme propionate A
		C1	-3.50	Y706, L337, M336, W306 (the other NOS monomer)
C1=	sp ² CH aromatic or vinyl	S	-5.30	P565, A566, V567, F584, S585, G586, heme
		M	-4.0	D597, heme propionate A
		C1	-3.30	Y706, L337, M336, W306 (the other NOS monomer)
NM3	trimethylammonium cation	S	-12.50	P565, A566, V567, F584, S585, G586, heme
		M	-10.00	D597, heme propionate A
		C1	-8.20	Y706, L337, M336, W306 (the other NOS monomer)
N1+	sp ³ amine NH cation	M	-11.00	D597, Y588
		M	-10.00	heme, Y706
		S	-9.50	E592
		M	-8.50	heme propionate A and D
N2+	sp ³ amine NH ₂ cation	M	-13.50	D597, Y588
		S	-12.00	E592, W587
		M	-10.50	heme propionate A and D
Cl	organic chlorine atom	S	-7.50	P565, A566, V567, F584, S585, G586, heme
		M	-6.00	D597, heme propionate
		C1	-5.20	Y706, L337, M336, W306 (the other NOS monomer)
F	organic fluorine atom	M	-4.80	D597, heme propionate A
		S	-4.30	P565, A566, V567, F584, S585, G586, heme
		C1	-2.70	Y706, L337, M336, W306 (the other NOS monomer)

Table 3

Minima found by MCSS in the active site of rat nNOS

MCSS functional groups	Initial number of copies	Number of Minima	Range of U_{bind}^a for minima (kcal/mol)	Selected minima		residues/cofactors involved
				from	To U_{bind} ; Pocket	
Benzene	2500	27	-1.75	-24.16	No.1: -24.16; S No.7: -13.47; C1	V567, F584, heme M336, L337, Y706, W306 (the other NOS monomer)
Cyclohexane	5000	98	-0.09	-9.80	No.8: -12.99; M No.1: -9.80; S No.3: -9.02; M No.6: -7.08; C1	D597, heme propionate A V567, F584, heme D597, heme propionate A M336, L337, Y706, W306 (the other NOS monomer)
isobutene	5000	22	-5.75	-11.29	No.1: -11.29; S No.3: -7.33; M No.13: -6.12; C1	V567, F584, heme D597, heme propionate A M336, L337, Y706, W306 (the other NOS monomer)
n-butane	5000	224	-2.82	-10.86	No.1: -10.85; S No.12: -7.79; M No.52: -5.70; C1	V567, F584, heme D597, heme propionate A M336, L337, Y706, W306 (the other NOS monomer)
Propane	5000	84	-1.55	-9.99	No.1: -9.99; S No.6: -6.50; M No.14: -5.71; C1	V567, F584, heme D597, heme propionate A M336, L337, Y706, W306 (the other NOS monomer)
trimethylamine ion	5000	28	-2.18	-87.43	No.1: -87.43; M No.2: -82.79; M No.4: -80.64; M No.7: -73.98; M No.22: -32.36; S	D597, E592 heme propionate A and D heme propionate A heme propionate D E592
dimethylamine ion	5000	35	-0.31	-131.52	No.1: -131.52; M No.6: -126.30; M No.8: -110.59; M No.11: -102.92; M	heme propionate A and D E592, D597 heme propionate A heme propionate D

MCSS functional groups	Initial number of copies	Number of Minima	Range of U_{bind}^a for minima (kcal/mol)	Selected minima	
				from	to
				U_{bind}	Pocket
					residues/cofactors involved

^a U_{bind} , the binding energy for a given functional group in each minimized replica obtained from the MCSS calculations, is defined as $U_{\text{bind}} = U_{\text{protein-group}} - U_{\text{group}}^0$, where $U_{\text{protein-group}}$ represents the nonbonded interactions between nNOS and the given functional group. U_{group} represents the internal energy of the functional group within the complex, and U_{group}^0 represents the internal energy of the isolated functional group in vacuum.

Table 4

Inhibition of NOS isozymes by synthetic inhibitors

Compounds	K_i (μM) [*]			Selectivity	
	nNOS	eNOS	iNOS	n/e	n/i
(\pm)-7	1.18	1450	161	1230	136
(\pm)-8	2.42	1450	238	600	98
(\pm)-9	2.3	1450	297	632	129
(\pm)-10	3.33	140	195	42	59
(\pm)-11	1.36	424	200	312	147
(\pm)-12	1.26	243	174	193	138
(\pm)-13	2.74	181	425	66	155
(\pm)-14	3.34	108	222	32	66
(\pm)-15	0.098	283	5.84	2890	60
(\pm)-16	0.085	85	8.95	1000	106
(\pm)-17	0.104	83	9.48	800	91
(\pm)-18	0.197	84	14.1	428	72
(\pm)-19	0.144	130	7.97	905	55
(\pm)-20	0.206	116	13.6	564	66
(\pm)-21	0.159	72	9.01	451	57
(\pm)-22	0.157	41	3.56	260	23
(\pm)-23	0.110	30	7.7	272	70
(\pm)-24	0.024	78	5.4	3230	222
(\pm)-25	0.027	18	4.6	656	170
(\pm)-26	0.014	28	4.06	2000	290
(\pm)-27	18.8	141	232	7.5	12
(\pm)-28	0.551	164	10.6	297	19
(\pm)-29	0.136	40.0	12.2	294	90
(\pm)-30	0.393	125	22.8	319	58
(\pm)-31	0.326	92.4	38.2	284	117
(\pm)-32	1.21	48.9	56.6	40	47

* The apparent K_i values are represented as the mean from two or more independent experiments performed in duplicate with five or six data points each and correlation coefficients of 0.89-0.99. The experimental standard deviations were less than 10%.

Table 5
The physicochemical data related to the absorption and biomembrane permeability of inhibitors

Compounds	ClogP	TPSA	ClogD (pH=7.4)	Hb-A	Hb-D	MW	RB
1	-7.000	217.968	-5.42	10	10	318.338	9
2	-6.267	203.972	-6.57	10	9	330.349	7
3	-6.172	203.972	-6.4	10	9	330.349	7
4	-5.787	157.803	-5.88	7	8	247.303	8
5	-3.270	157.803	-4.07	6	8	323.401	8
6	-1.329	88.992	-5.16	4	6	235.331	5
7	1.364	74.996	-2.82	4	5	325.456	8
16	2.576	74.996	-1.81	4	5	373.928	8
17	2.576	74.996	-1.72	4	5	373.928	8
24	2.052	74.996	-2.44	4	5	353.509	9
25	2.195	74.996	-2.38	4	5	371.5	9
26	2.195	74.996	-2.36	4	5	371.5	9
29	2.885	74.996	-1.49	4	5	387.955	8
30	3.220	66.207	-0.91	4	4	387.955	8
31	2.838	66.207	-1.81	4	4	385.527	9
32	3.432	57.418	-1	4	3	399.554	9

Hb-A: sum of H-bond acceptors; Hb-D: sum of H-bond donors; MW: Molecular Weights; RB: number of freely rotating bonds; ClogP values for the inhibitors were calculated by ClogP program version 4.2 in the SYBYL 6.8 environment with a special license from BioByte Corporation.³⁷ Log D values for the inhibitors were calculated by ACD/LogD at pH 7.4.³⁸ The topological molecular polar surface areas (TPSA) were calculated by the atom-based method of Ertl, et al.³⁶